Macrocyclic compounds and their use as kinase inhibitors

By designing macrocyclic compounds targeting the TYK2 pseudokinase domain, the problem of insufficient selectivity of existing JAK inhibitors has been solved, achieving highly efficient inhibition of TYK2 kinase, improving the therapeutic effect of autoimmune diseases and reducing adverse reactions.

CN118946559APending Publication Date: 2024-11-12BLOSSOMHILL THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380021606.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-28
Filing Date
2023-01-03
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing JAK inhibitors suffer from insufficient selectivity and adverse effects in the treatment of human autoimmune diseases, and are difficult to effectively target the TYK2 pseudokinase domain, resulting in poor treatment efficacy and safety issues.

Method used

A series of macrocyclic compounds were developed that target the TYK2 pseudokinase domain through specific structural design. Compounds of formulas I to XII or their pharmaceutically acceptable salts were designed to inhibit TYK2 kinase, reduce inhibition of other JAK family members, and improve therapeutic selectivity and safety.

Benefits of technology

It improves the selective inhibition of TYK2 kinase, reduces the inhibition of other JAK family members, enhances the therapeutic effect on autoimmune diseases such as multiple sclerosis, Crohn's disease, and psoriasis, and reduces the occurrence of adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004990892020000031
    Figure BDA0004990892020000031
  • Figure BDA0004990892020000061
    Figure BDA0004990892020000061
  • Figure BDA0004990892020000062
    Figure BDA0004990892020000062
Patent Text Reader

Abstract

The present invention relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat diseases, such as autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Serial No. 63 / 296,705 filed on January 5, 2022 and U.S. Provisional Application Serial No. 63 / 435,654 filed on December 28, 2022, the entire disclosures of which are incorporated herein by reference. Technical Field

[0003] The present invention relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat diseases such as human autoimmune diseases. Background Art

[0004] Protein kinases are tightly regulated signal transducers that coordinate the activation of signal cascades by phosphorylating target proteins in response to extracellular and intracellular stimuli. The human genome encodes about 518 protein kinases (Manning G et al., The protein kinase complement of the human genome. Science. 2002, 298: 1912–34). Disorders in kinase activity are associated with many diseases (including autoimmune diseases, cardiovascular diseases, degenerative diseases, immune diseases, infectious diseases, inflammatory diseases, and metabolic diseases) (Levitzki, A. Protein kinase inhibitors as atherapeutic modality as a therapeutic approach. Acc. Chem. Res. 2003, 36: 462–469). The molecular basis for various diseases includes kinase gain- and loss-of-function mutations, gene amplification and deletion, splicing changes and translocations (Wilson LJ et al., New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome. Autoimmune Disease Res. 2018, 78: 15-29). The key role of kinases in autoimmune and other diseases makes them attractive targets for drug discovery, with 52 small molecule kinase inhibitors approved and 46 of them used for targeted therapy of autoimmune diseases (Roskoski R Jr., Properties of FDA-approved Small Molecule Protein Kinase Inhibitors: A 2020 Update. Pharmacol Res 2020, 152: 104609). Cytokine signaling is critical for cell growth, hematopoiesis, and immune system function. Cytokine-mediated receptor dimerization induces intracellular activation of receptor-bound Janus kinases (JAKs), which then induce downstream transcriptional responses.The Janus kinase signal transducer and activator of transcription (JAK–STAT) pathway plays an important role in normal and pathological states of immune-mediated inflammatory diseases (O'Shea JJ et al., The JAK–STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015, 66:311–28). Targeting JAK-related pathways with JAK inhibitors has achieved clinical success in a wide range of diseases, including ruxolitinib and fedratinib for myeloproliferative neoplasms, and tofacitinib, upadacitinib, and baricitinib for rheumatoid arthritis and other immune-mediated inflammatory diseases (McLornan DP et al., Lancet. 2021, 398:803-816). However, achieving isoform-selective JAK inhibitors is challenging and almost all of these approved kinase domain ATP-competitive JAK inhibitors present significant undesirable adverse effects due to inhibition of multiple JAK family members. The JAK kinase is a large multi-domain protein that includes a FER domain [JH6-JH7] and an SH2 domain [JH3-JH5] (both of which mediate receptor interactions), a pseudokinase domain [JH2] with regulatory functions, and a kinase catalytic domain [JH1] (Garrido-Trigo A and Salas Journal A, Journal of Crohn's and Colitis, 2020, S713–S724). The pseudokinase domain regulates the kinase domain by sterically inhibiting ATP binding and / or reducing the flexibility of the kinase active site required for catalysis (Patrick J et al., PNAS 2014 111: 8025-8030). Although JAK family members share high sequence homology within the catalytic domain, the distinguishing pseudokinase domain (JH2) within the JAK family provides an ideal "allosteric" site for the development of highly selective JAK inhibitors. TYK2, a member of the JAK family, plays an important role in regulating the signaling of a wide range of pro-inflammatory cytokines, including IL12, IL23, and type 1 interferon (IFNα).Highly selective TYK2 inhibitors are desired for an optimal benefit-safety balance in the treatment of human autoimmune diseases, including multiple sclerosis, Crohn's disease, psoriasis, etc. (Leitner, NR et al., Tyrosine kinase 2-surveillant of tumours and bona fide oncogene. Cytokine 2017, 89, 209-218).

[0005] Therefore, the discovery and development of highly selective inhibitors of the JAK family, such as TYK2 inhibitors that target the TYK2 JH2 pseudokinase domain, represent novel therapeutic inventions for the treatment of human autoimmune diseases, including multiple sclerosis, Crohn's disease, psoriasis, and others. Summary of the invention

[0006] In one aspect, the present invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof,

[0007]

[0008] in

[0009] A is

[0010] B is

[0011] Each L is independently -C(R 3 )(R 4 )-、-C(O)-、-O-、-N(R 5 )-, -S-, -S(O)- or -S(O)2-, with the restriction (L) n Does not include –OO-, –OS-, -SS-, or –ON(R 5 )-key, and (L) n -N(R 9 )-Not included-ON(R 9 )-、–SN(R 9 )-key;

[0012] Y and Y 1 Each independently is O or S;

[0013] R1, R 1a and R 2Each of the above is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0014] R 2a , R 5 , R 8 and R 9 Each of the following is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e Rf 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0015] R 2bis C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl or 3- to 4-membered heterocycloalkyl, wherein each hydrogen atom in C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl and 3- to 4-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, -O(H or C1-C2 alkyl), -OC(O)C1-C2 alkyl, -OC(O)N(H or C1-C2 alkyl)2, -OS(O)C1-C2 alkyl, -OS(O)2C1 -C2 alkyl, -OS(O)N(H or C1-C2 alkyl)2, -OS(O)2N(H or C1-C2 alkyl)2, -S(H or C1-C2 alkyl), -S(O)C1-C2 alkyl, -S(O)2C1-C2 alkyl, -S(O)N(H or C1-C2 alkyl)2, -S(O)2N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)C(O)C1-C2 alkyl, -N(H or C1-C2 C(O)O(H or C1-C2 alkyl), -N(H or C1-C2 alkyl)C(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)2C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)2N(H or C1-C2 alkyl)2, -C(O)C1-C2 alkyl , -C(O)O(H or C1-C2 alkyl), -C(O)N(H or C1-C2 alkyl)2, -P(H or C1-C2 alkyl)2, -P(O)(H or C1-C2 alkyl)2, -P(O)2(H or C1-C2 alkyl)2, -P(O)N(H or C1-C2 alkyl)2, -P(O)2N(H or C1-C2 alkyl)2, -P(O)O(H or C1-C2 alkyl), -P(O)2O(H or C1-C2 alkyl), -CN or -NO2;

[0016] Each R 3 and R 4 are independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR c 、-OC(O)R c 、-OC(O)NR c R d 、-OC(=N)NR c R d 、-OS(O)R c 、-OS(O)2R c, -OS(O)NR c R d , -OS(O)2NR c R d , -SR c , -S(O)R c , -S(O)2R c , -S(O)NR c R d , -S(O)2NR c R d , -NR c R d , -NR c , -NR d , -N(C(O)R c )(C(O)R d , -NR c , -NR d , -NR c , -NR c R d , -NR c , -NR c R d , -NR c , -NR d , -NR c , -NR d , -NR c , -NR c R d , -NR c , -NR c R d , -C(O)R c , -C(O)OR c , -C(O)NR c R d , -C(=N)NR c R d , -PR c R d , -P(O)R c R d , -P(O)2R c R d , -P(O)NR c R d , -P(O)2NR c R d , -P(O)OR c , -P(O)2OR c , -CN, -NO2, or R 3 , R 4 and R 5The two of them and the atoms to which they are connected together form a C3-C6 cycloalkyl or a 4- to 8-membered heterocycloalkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0017] R 6 and R 7 Each of the above is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)Ra R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2;

[0018] Each R a , R b , R c , R d , R e and R f are independently selected from H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, C1-C6 alkyl-C6-C 10 The group consisting of aryl and 5- to 10-membered heteroaryl; and

[0019] n is 2, 3, 4, 5, 6, 7 or 8.

[0020] In some embodiments, L does not contain -N(R 5 In some embodiments, each L is independently -C(R 3 )(R 4 )-, -C(O)-, -O-, -S-, -S(O)- or -S(O)2-, with the restriction that (L) n does not contain –OO-, -SS-, or –OS- bonds. In some embodiments, R 2 No – OR a In some embodiments, R 2 is H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a Rb 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e Rf 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0021] In some embodiments, the present invention provides a compound of formula II or a pharmaceutically acceptable salt thereof,

[0022]

[0023] Among them, A, B, L, R 7 , R 8 , R 9 and n are as described herein.

[0024] In some embodiments, the present invention provides a compound of formula III or a pharmaceutically acceptable salt thereof,

[0025]

[0026] Among them, B, L, R 1 , R 1a , R 7 , R 8 , R 9 and n are as described herein.

[0027] In some embodiments, the present invention provides a compound of formula IV or a pharmaceutically acceptable salt thereof,

[0028]

[0029] Among them, B, L, R 1 , R 7 , R 8 , R 9 and n are as described herein.

[0030] In some embodiments, the present invention provides a compound of formula V or a pharmaceutically acceptable salt thereof,

[0031]

[0032] Among them, L, R 2 , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0033] In some embodiments, the present invention provides a compound of formula VI or a pharmaceutically acceptable salt thereof,

[0034]

[0035] Among them, L, R 2a , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0036] In some embodiments, the present invention provides a compound of formula VII or a pharmaceutically acceptable salt thereof,

[0037]

[0038] Among them, L, R 1 , R 1a , R 2 , R 2b , R7 , R 8 , R 9 and n are as described herein.

[0039] In some embodiments, the present invention provides a compound of formula VIII or a pharmaceutically acceptable salt thereof,

[0040]

[0041]

[0042] Among them, L, R 1 , R 2 , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0043] In some embodiments, the present invention provides a compound of formula IX or a pharmaceutically acceptable salt thereof,

[0044]

[0045] Among them, L, R 1 , R 1a , R 2a , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0046] In some embodiments, the present invention provides a compound of formula X or a pharmaceutically acceptable salt thereof,

[0047]

[0048] Among them, L, R 1 , R 2a , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0049] In some embodiments, the present invention provides a compound of formula XI or a pharmaceutically acceptable salt thereof,

[0050]

[0051] Among them, L, R 1 , R 1a , R 2 , R 2b , R 7 and n are as described herein.

[0052] In some embodiments, the present invention provides a compound of Formula XII or a pharmaceutically acceptable salt thereof,

[0053]

[0054] Among them, L, R 1 , R 1a , R 2a , R 2b , R 7 and n are as described herein.

[0055] In some embodiments, Ring A is In some embodiments, Ring B is In some embodiments, Ring B is not

[0056] In some embodiments, R 7 is H, deuterium, C1-C6 alkyl, fluorine, chlorine or -CN. In some embodiments, R 7 is H. In some embodiments, R 7 In some embodiments, R 7 is a C1-C6 alkyl group. In some embodiments, R 7 In some embodiments, R 7 In some embodiments, R 7 Yes-CN.

[0057] In some embodiments, Ring B is And R 7 is H. In some embodiments, Ring A is Ring B is And R 7 is H. In some embodiments, Ring B is And R 7 is not H. In some embodiments, Ring A is Ring B is And R 7 is not H. In some embodiments, Ring B is And R 7 is -F, -Cl or -CN. In some embodiments, Ring B is And R 7 is -Cl or -CN. In some embodiments, Ring A is Ring B is And R 7 is -F, -Cl or -CN. In some embodiments, Ring A is Ring B is And R 7 is -Cl or -CN. In some embodiments, Ring B is And R 7 is -F. In some embodiments, Ring B is And R 7 is -Cl. In some embodiments, Ring B is And R 7 is -CN. In some embodiments, Ring A is Ring B is And R 7 is -F. In some embodiments, Ring A is Ring B is And R 7 is -Cl. In some embodiments, Ring A is Ring B is R 7 Yes – CN.

[0058] In certain embodiments of the above aspects, the compound of formula (I) to (XII) is selected from compounds of their class described or exemplified in the [embodiment] below.

[0059] In other aspects, the present invention relates to a pharmaceutical composition comprising at least one compound of formula (I) to (XII) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable excipient.

[0060] In other aspects, the present invention relates to compounds of formula (I) to (XII) or pharmaceutically acceptable salts thereof for use as medicaments.

[0061] In other aspects, the present invention relates to a method of treating a disease such as an autoimmune disease, comprising administering to a subject in need of such treatment an effective amount of at least one compound of Formula (I) to (XII) or a pharmaceutically acceptable salt thereof.

[0062] In other aspects, the present invention relates to the use of a compound of formula (I) to (XII) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease (such as an autoimmune disease), and the use of such compounds and salts in treating such diseases.

[0063] In other aspects, the present invention relates to a method of inhibiting tyrosine kinases such as TYK2, comprising contacting a cell comprising one or more kinases with an effective amount of at least one compound of formula (I) to (XII) or a pharmaceutically acceptable salt thereof, and / or with at least one pharmaceutical composition of the present invention, wherein the contacting is in vitro, ex vivo or in vivo.

[0064] From the following detailed description and through the practice of the present invention, other embodiments, features and advantages of the present invention will become apparent. The compounds of the present invention may be described as embodiments in any of the clauses listed below. It should be understood that any embodiment described herein may be used in combination with any other embodiment described herein to the extent that the embodiments do not contradict each other.

[0065] 1. A compound of formula I or a pharmaceutically acceptable salt thereof,

[0066]

[0067] in

[0068] A is

[0069] B is

[0070] Each L is independently -C(R 3 )(R 4 )-、-C(O)-、-O-、-N(R 5 )-, -S-, -S(O)- or -S(O)2-, with the restriction (L) n Does not include –OO-, –OS-, -SS-, or –ON(R 5 )-key, and (L) n -N(R 9 )-Not included-ON(R 9 )-、–SN(R 9 )-key;

[0071] Y and Y 1 Each independently is O or S;

[0072] R1, R 1a and R 2 Each of the above is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a Rb 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e Rf 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0073] R 2a , R 5 , R 8 and R 9 Each of the following is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10aryl or 5- to 10-membered heteroaryl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e Rf 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0074] R 2b is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl or 3- to 4-membered heterocycloalkyl, wherein each hydrogen atom in C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl and 3- to 4-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, -O(H or C1-C2 alkyl), -OC(O)C1-C2 alkyl, -OC(O)N(H or C1-C2 alkyl)2, -OS(O)C1-C2 alkyl, -OS(O)2C1 -C2 alkyl, -OS(O)N(H or C1-C2 alkyl)2, -OS(O)2N(H or C1-C2 alkyl)2, -S(H or C1-C2 alkyl), -S(O)C1-C2 alkyl, -S(O)2C1-C2 alkyl, -S(O)N(H or C1-C2 alkyl)2, -S(O)2N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)C(O)C1-C2 alkyl, -N(H or C1-C2 C(O)O(H or C1-C2 alkyl), -N(H or C1-C2 alkyl)C(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)2C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)2N(H or C1-C2 alkyl)2, -C(O)C1-C2 alkyl , -C(O)O(H or C1-C2 alkyl), -C(O)N(H or C1-C2 alkyl)2, -P(H or C1-C2 alkyl)2, -P(O)(H or C1-C2 alkyl)2, -P(O)2(H or C1-C2 alkyl)2, -P(O)N(H or C1-C2 alkyl)2, -P(O)2N(H or C1-C2 alkyl)2, -P(O)O(H or C1-C2 alkyl), -P(O)2O(H or C1-C2 alkyl), -CN or -NO2;

[0075] Each R 3 and R 4 are independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR c 、-OC(O)R c 、-OC(O)NRc R d 、-OC(=N)NR c R d 、-OS(O)R c 、-OS(O)2R c 、-OS(O)NR c R d 、-OS(O)2NR c R d 、-SR c 、-S(O)R c 、-S(O)2R c 、-S(O)NR c R d 、-S(O)2NR c R d 、-NR c R d 、-NR c C(O)R d 、-N(C(O)R c )(C(O)R d )、-NR c C(O)OR d 、-NR c C(O)NR c R d 、-NR c C(=N)NR c R d 、-NR c S(O)R d 、-NR c S(O)2R d 、-NR c S(O)NR c R d 、-NR c S(O)2NR c R d 、-C(O)R c 、-C(O)OR c 、-C(O)NR c R d 、-C(=N)NR c R d 、-PR c R d 、-P(O)R c R d 、-P(O)2R c R d 、-P(O)NR c R d 、-P(O)2NR c Rd 、-P(O)OR c 、-P(O)2OR c , -CN, -NO2, or R 3 , R 4 and R 5 The two of them and the atoms to which they are connected together form a C3-C6 cycloalkyl or a 4- to 8-membered heterocycloalkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0076] R 6 and R 7 Each of the above is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2; or R 6 and R 7 Together with the carbon to which it is attached, it forms a C4-C6 cycloalkyl, a 4- to 7-membered heterocycloalkyl, or a C6-C 10 Aryl, among which C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NRe S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution;

[0077] Each R a , R b , R c , R d , R e and R f are independently selected from H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, C1-C6 alkyl-C6-C 10 The group consisting of aryl and 5- to 10-membered heteroaryl; and

[0078] n is 2, 3, 4, 5, 6, 7 or 8.

[0079] 2. A compound according to item 1, which has formula II

[0080]

[0081] or a pharmaceutically acceptable salt thereof.

[0082] 3. A compound according to item 1, which has formula III

[0083]

[0084] or a pharmaceutically acceptable salt thereof.

[0085] 4. A compound according to item 1 or 2, which has formula IV

[0086]

[0087] or a pharmaceutically acceptable salt thereof.

[0088] 5. A compound according to item 1 or 2, which has formula V

[0089]

[0090] or a pharmaceutically acceptable salt thereof.

[0091] 6. A compound according to item 1 or 2, which has formula VI

[0092]

[0093] or a pharmaceutically acceptable salt thereof.

[0094] 7. A compound according to any one of clauses 1 to 3, which has formula VII

[0095]

[0096] or a pharmaceutically acceptable salt thereof.

[0097] 8. A compound according to item 1 or 2, which has formula VIII

[0098]

[0099] or a pharmaceutically acceptable salt thereof.

[0100] 9. A compound according to any one of clauses 1 to 3, which has the formula IX

[0101]

[0102] or a pharmaceutically acceptable salt thereof.

[0103] 10. A compound according to item 1 or 2, which has the formula X

[0104]

[0105] or a pharmaceutically acceptable salt thereof.

[0106] 11. A compound according to any one of clauses 1 to 3, which has the formula XI

[0107]

[0108]

[0109] or a pharmaceutically acceptable salt thereof.

[0110] 12. A compound according to any one of clauses 1 to 3, which has formula XII

[0111]

[0112] or a pharmaceutically acceptable salt thereof.

[0113] 13. A compound according to any of the preceding clauses or a pharmaceutically acceptable salt thereof, wherein R 1 When present, it is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is independently optionally substituted with deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R eR f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2, or R 1 It is H, -CN or methyl.

[0114] 14. A compound according to any one of clauses 1 to 3, 5 to 7, 9, 11, 12 or 13, or a pharmaceutically acceptable salt thereof, wherein R 1a When present, it is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is independently optionally substituted with deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)Re 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2, or R 1a It is H, -CN or methyl.

[0115] 15. A compound according to any one of clauses 1 to 5, 7, 8, 11, 13 or 14, or a pharmaceutically acceptable salt thereof, wherein R 2 When present, it is H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2Rb 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NRe S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 2 When present, it is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is independently optionally substituted with deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR eR f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 2 When present it is H, -CN or methyl.

[0116] 16. A compound according to any one of clauses 1 to 4, 6, 9, 10 or 12 to 15, or a pharmaceutically acceptable salt thereof, wherein R 2a When present, it is H or C1-C6 alkyl, wherein each hydrogen atom in C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e Rf 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 2a When present it is H or methyl.

[0117] 17. A compound according to any of the preceding clauses or a pharmaceutically acceptable salt thereof, wherein R 2b When present, it is C1-C4 alkyl or C3-C4 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl and C3-C4 cycloalkyl is independently optionally substituted with deuterium or halogen; or R 2b It is methyl, ethyl, isopropyl or cyclopropyl.

[0118] 18. A compound according to any of the preceding clauses, or a pharmaceutically acceptable salt thereof, wherein n is 3.

[0119] 19. The compound of any one of clauses 1 to 17, or a pharmaceutically acceptable salt thereof, wherein n is 4.

[0120] 20. The compound of any one of clauses 1 to 17, or a pharmaceutically acceptable salt thereof, wherein n is 5.

[0121] 21. The compound of any one of clauses 1 to 17, or a pharmaceutically acceptable salt thereof, wherein n is 6.

[0122] 22. A compound or a pharmaceutically acceptable salt thereof as in any of the preceding clauses, wherein each L is independently selected from -C(O)-, -O-, -CH2-, -C(H)(CH3)-, -C(H)(OH)-, -C(H)(C(O)OR c )-、-C(H)(C(O)NR c R d )-, -NH- and -NCH3-; or each L is independently selected from the group consisting of -C(O)-, -O-, -CH2-, -C(H)(CH3)-, -C(H)(OH)-, -C(H)(C(O)OR c )- and -C(H)(C(O)NR c R d )-composed of groups.

[0123] 23. The compound of any one of clauses 1 or 13 to 22, or a pharmaceutically acceptable salt thereof, wherein Y is O.

[0124] 24. A compound according to any one of clauses 1 or 13 to 23, or a pharmaceutically acceptable salt thereof, wherein Y 1 It's O.

[0125] 25. A compound according to any one of clauses 1 or 13 to 25, or a pharmaceutically acceptable salt thereof, wherein R 6 When present, is independently H, deuterium, fluorine, chlorine, -CN or methyl.

[0126] 26. A compound according to any one of the preceding clauses or a pharmaceutically acceptable salt thereof, wherein R 7 are independently H, deuterium, fluorine, chlorine, -CN or methyl.

[0127] 27. A compound according to any one of clauses 1 to 10 or 13 to 26, or a pharmaceutically acceptable salt thereof, wherein R 8 It is H or methyl.

[0128] 28. A compound according to any one of clauses 1 to 10 or 13 to 27, or a pharmaceutically acceptable salt thereof, wherein R 9 It is H or methyl.

[0129] 29. A compound according to any of the preceding clauses or a pharmaceutically acceptable salt thereof, wherein - (L) n-is-(CH2)2-,-(CH2)3-,-(CH2)4-,-(CH2)5-,-(CH2)6-,-C(O)NH-(CH2)2O(CH2)2-,-C(O)N(CH3)-(CH2)2O(CH2)2-,-NHC(O)CH2O(CH2)2-,-N(CH3)-C(O)CH2O(CH2)2-,-CH2O(CH2)2-,-CH2O(CH2)3-,-CH2O(C(CH3)H)2-,-(CH2)2O(CH2)2-,-CH2OCH2(C(CH3)H)-,-(CH2)2O(CH2)2-,-CH2OCH2(C(CH3)H)-,-(CH2)2OCH2(C(CH3)H)-,-(CH2)2OCH2(C(CH3)H)-,-(CH2 )2S(CH2)2-、-O(CH2)2S(CH2)2-、-(CH2)2SO2(CH2)2-、-O(CH2)2SO2(CH2)2-、-(CH2)2SO(CH2)2-、-O(CH2)2SO(CH2)2-、-(CH2)2O(C(H)(C(O)N(H) (CH3))-CH2-、-(CH2)2O(C(H)(C(O)N(CH3)2)-CH2-、-(CH2)2O(C(H)(C(O)OCH3)-CH2-、-(CH2)3O(CH2)2-、-(CH2)2O(CH2)3-、-CH2CH(CH3)-O(CH2) 2-、-CH(CH3)-CH2O(CH2)2-、-O(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)2CH(CH3)-、-OCH2O(CH2)2-、-O-CH2CH(OH)CH2-、-O-(CH2)2O(CH2)2-、-O-CH2CH(CH3)-O(CH2)2-、-O-CH(CH3)-CH2O(CH2)2-、-O-(CH2)2NH-(CH2)2-、-O-CH2CH(CH3)-NH-(CH2)2-、-O-CH(CH3)-CH2NH-(CH2)2-、-O-CH(CH3)-CH2NH-(CH2)2-、-CH2NH -(CH2)2-、-(CH2)2NH-(CH2)2-、-CH2CH(CH3)-NH-(CH2)2-、-CH(CH3)-CH2NH-(CH2)2-、-O-(CH2)2N(CH3)-(CH2)2-、-O-CH2CH(CH3)-N(CH3)-(CH2) )2-、-O-CH(CH3)-CH2N(CH3)-(CH2)2-、-CH2N(CH3)-(CH2)2-、-CH2N(CH2CH3)-(CH2)2-、-CH2N((CH2)2CH3)-(CH2)2-、-CH2N(CH(CH3)2)-(CH2)2-、-(CH2)2N(CH3)-(CH2)2-, -CH2CH(CH3)-N(CH3)-(CH2)2- or -O-CH(CH3)-CH2N(CH3)-(CH2)2-; or -O(CH2)2-, -O(CH2)3-, -O(CH2)4-, -CH2OCH2(C(CH3)H)-, -CH2O(CH2)2- or -CH2O(CH2)3-; or -O(CH2)3-, -CH2OCH2(C(CH3)H)- or -CH2O(CH2)2-. 、

[0130] 30. A compound according to clause 1 or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of: [3a(4)Z]-6,9,15,16-tetramethyl-9,10,11,12-tetrahydro-15H-1,17-(ethylenediyl)pyrazolo[4,3-n]dipyrrolo[3,2-g:3',4'-j][1,5]oxazacyclopentadecine-3,8(2H,5H)-dione;

[0131] [3a(4)Z]-6,9,15,16-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0132] [3a(4)Z,10R]-20-chloro-6,10,15-trimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0133] [3a(4)Z,10R]-20-chloro-10,15-dimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0134] [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0135] [3a(4)Z,10S]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0136] [3a(4)Z]-20-chloro-6,9,15-trimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0137] [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-f]pyrazolo[4,3-m]pyrrolo[3,4-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0138] [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,16-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0139] [3a(4)Z,10R]-6,9,10,15-tetramethyl-3,8-dioxo-3,5,8,9,10,11,13,15-octahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-20-carbonitrile;

[0140] [3a(4)Z,10R]-20-fluoro-6,9,10,15,16-pentamethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0141] [3a(4)Z,10R]-20-chloro-6,9,10,15,16-pentamethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; and

[0142] [3a(4)Z,10R]-20-Fluoro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-vinyl-bridged pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione.

[0143] 31. A pharmaceutical composition comprising at least one compound according to any one of clauses 1 to 30 or a pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipients.

[0144] 32. A method of treating a disease such as an autoimmune disease, comprising administering to a subject in need of such treatment an effective amount of a compound according to any one of clauses 1 to 30, or a pharmaceutically acceptable salt thereof.

[0145] 33. A compound according to any one of clauses 1 to 30, or a pharmaceutically acceptable salt thereof, for use in a method of treating an autoimmune disease in a subject.

[0146] 34. A compound according to any one of clauses 1 to 30, or a pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease in a subject.

[0147] 35. Use of a compound according to any one of clauses 1 to 30, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease in a subject. DETAILED DESCRIPTION

[0148] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described, as such may, of course, vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only, and is not intended to be limiting, as the scope of the present invention will be limited only by the appended claims.

[0149] For the sake of brevity, the disclosures of the publications (including patents) cited in this specification are incorporated herein by reference. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. All patents, applications, published applications and other publications mentioned herein are incorporated by reference in their entirety. If the definitions stated in the sections are contrary to or otherwise inconsistent with the definitions stated in the patents, applications or other publications incorporated herein by reference, the definitions stated in the sections prevail over the definitions incorporated herein by reference.

[0150] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that claims may be drafted to exclude any optional elements. Thus, the statement is intended to serve as antecedent basis for use of such terminology as "solely," "only," and the like in connection with the recitation of claim elements or use of a "negative" limitation.

[0151] As used herein, the terms "including," "containing," and "comprising" are used in their open, non-limiting sense.

[0152] In order to provide a more concise description, some of the quantitative statements given herein are not quantitatively expressed with the term "about". It should be understood that, regardless of whether the term "about" is explicitly used, each amount given herein represents an actual given value, and also represents an approximate value that will be reasonably inferred to the given value based on the general technology in the art, including equivalents and approximate values ​​caused by the experimental and / or measurement conditions of the given value. Whenever the yield is given as a percentage, the yield refers to the mass of the entity that gives the yield relative to the maximum amount of the same entity that can be obtained under specific stoichiometric conditions. Concentrations given as percentages refer to mass ratios unless otherwise specified.

[0153] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art. Although any methods and materials similar to or equivalent to those described herein may also be used to implement or test the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe methods and / or materials cited in conjunction with the publications.

[0154] Unless otherwise indicated, the methods and techniques of the present examples are generally performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout the present specification. See, e.g., Loudon, Organic Chemistry, 4th ed., New York: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed., Wiley-Interscience, 2001.

[0155] The chemical nomenclature of the compounds described herein is generally derived using the commercially available ACD / Name 2020 (ACD / Labs) or ChemBioDraw Ultra 20.0 (Perkin Elmer).

[0156] It should be understood that certain features of the invention described in the context of separate embodiments for clarity may also be provided in combination in a single embodiment. Conversely, certain features of the invention described in the context of separate embodiments for brevity may also be provided individually or in any suitable sub-combination. All combinations of embodiments with respect to chemical groups represented by variables are specifically encompassed by the present invention and disclosed herein, as are each and every combination individually and explicitly disclosed to the extent that such combinations encompass compounds that are stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity). In addition, all sub-combinations of chemical groups listed in the embodiments describing such variables are also specifically encompassed by the present invention and disclosed herein, as are each and every such sub-combination of chemical groups individually and explicitly disclosed herein.

[0157] Chemical Definition

[0158] The term "alkyl" refers to a straight or branched monovalent hydrocarbon group. The term "alkylene" refers to a straight or branched divalent hydrocarbon group. In some embodiments, it may be advantageous to limit the number of atoms in "alkyl" or "alkylene" to a specific range of atoms, such as C1-C 20 Alkyl or C1-C 20 Alkylene, C1-C 12 Alkyl or C1-C 12 Alkylene, or C1-C6 alkyl or C1-C6 alkylene. Examples of alkyl include methyl (Me), ethyl (Et), n-propyl, isobutyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that are considered equivalent to any of the aforementioned examples according to the teachings provided by the general technician and herein. Examples of alkylene include methylene (-CH2-), ethylene ((-CH2-)2), n-propylene ((-CH2-)3), iso-propylene ((-C(H)(CH3)CH2-)), n-butylene ((-CH2-)4), etc. It should be understood that, as described herein, alkyl or alkylene may be unsubstituted or substituted. Alkyl or alkylene may be substituted by any substituent (including one or more of such substituents) in the various embodiments described herein.

[0159] The term "alkenyl" refers to a straight or branched monovalent hydrocarbon group having one or more double bonds. The term "alkenylene" refers to a straight or branched divalent hydrocarbon group having one or more double bonds. In some embodiments, it may be advantageous to limit the number of atoms in an "alkenyl" or "alkenylene" group to a specific range of atoms, such as C2-C 20 Alkenyl or C2-C 20 Alkenylene, C2-C 12 Alkenyl or C2-C 12 Alkenylene, or C2-C6 alkenyl or C2-C6 alkenyl. Examples of alkenyl include ethenyl / vinyl, allyl and but-3-ene-1-yl. Examples of alkenyl include ethenylene / vinylene (-CH=CH-), n-propenylene (-CH=CHCH2-), iso-propenylene (-CH=CH(CH3)-), etc. The term includes cis and trans isomers and mixtures thereof. It should be understood that, as described herein, alkenyl or alkenylene may be unsubstituted or substituted. Alkenyl or alkenylene may be substituted with any substituent in the various embodiments described herein, including one or more of such substituents.

[0160] The term "alkynyl" refers to a straight or branched monovalent hydrocarbon group having one or more triple bonds. The term "alkynylene" refers to a straight or branched divalent hydrocarbon group having one or more triple bonds. In some embodiments, it may be advantageous to limit the number of atoms in an "alkynyl" or "alkynylene" group to a specific range of atoms, such as C2-C 20 Alkynyl or C2-C 20 Alkynylidene, C2-C 12 Alkynyl or C2-C 12 Alkyne, or C2-C6 alkynyl or C2-C6 alkynyl. Examples of alkynyl include ethynyl (-C≡CH) and propargyl (-CH2C≡CH), but-3-yn-1,4-diyl (-C≡C-CH2CH2-), etc. It should be understood that, as described herein, alkynyl or alkynylene may be unsubstituted or substituted. Alkynyl or alkynylene may be substituted with any substituent in the various embodiments described herein, including one or more of such substituents.

[0161] The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic or polycyclic monovalent carbocyclic ring. The term "cycloalkylene" refers to a saturated or partially saturated, monocyclic or polycyclic divalent carbocyclic ring. In some embodiments, the number of atoms in "cycloalkyl" or "cycloalkylene" may be advantageously limited to a specific range of atoms, such as having 3 to 12 ring atoms. Polycyclic carbocyclic rings include fused, bridged, and spiral polycyclic systems. Illustrative examples of cycloalkyl include monovalent groups of the following entities, while cycloalkylene includes divalent groups of the following entities, which are in the form of properly bonded portions:

[0162]

[0163] In particular, the cyclopropyl moiety may be represented by the structure In particular, the cyclopropylene moiety can be represented by the structural formula Depicted. It should be understood that, as described herein, a cycloalkyl or cycloalkylene group may be unsubstituted or substituted. A cycloalkyl or cycloalkylene group may be substituted with any substituent in the various embodiments described herein, including one or more of such substituents.

[0164] The term "halogen" or "halo" means chlorine, fluorine, bromine or iodine.

[0165] The term "haloalkyl" refers to an alkyl group having one or more halogen substituents. Examples of haloalkyl groups include -CF3, -(CH2)F, -CHF2, -CH2Br, -CH2CF3, and -CH2CH2F. The term "haloalkylene" refers to an alkyl group having one or more halogen substituents. Examples of haloalkyl groups include -CF2-, -C(H)(F)-, -C(H)(Br)-, -CH2CF2-, and -CH2C(H)(F)-.

[0166] The term "aryl" refers to a monovalent all-carbon monocyclic or fused-ring polycyclic group having a completely conjugated π electron system. The term "arylene" refers to a monovalent all-carbon monocyclic or fused-ring polycyclic group having a completely conjugated π electron system. In some embodiments, it may be advantageous to limit the number of atoms in the "aryl" or "arylene" group to a specific range of atoms, such as a monovalent all-carbon monocyclic or fused-ring polycyclic group of 6 to 14 carbon atoms (C6-C 14 aryl), monovalent all-carbon monocyclic or condensed-ring polycyclic groups of 6 to 10 carbon atoms (C6-C 10 aryl), a divalent all-carbon monocyclic or condensed polycyclic group of 6 to 14 carbon atoms (C6-C 14 Arylene), divalent all-carbon monocyclic or condensed polycyclic groups of 6 to 10 carbon atoms (C6-C 10 Examples of aryl groups are, but are not limited to, phenyl, naphthyl, and anthracenyl. Examples of aryl groups are, but are not limited to, phenylene, naphthylene, and anthracenylene. It is understood that, as described herein, an aryl or arylene group may be unsubstituted or substituted. An aryl or arylene group may be substituted with any substituent in the various embodiments described herein, including one or more of such substituents.

[0167] The term "heterocycloalkyl" refers to a monovalent monocyclic or polycyclic ring structure, which is saturated or partially saturated, with one or more non-carbon ring atoms. The term "heterocycloalkylene" refers to a monovalent monocyclic or polycyclic ring structure, which is saturated or partially saturated, with one or more non-carbon ring atoms. In some embodiments, it is advantageous to limit the number of atoms in "heterocycloalkyl" or "heterocycloalkylene" to a specific range of ring atoms, such as 3 to 12 ring atoms (3- to 12 members), or 3 to 7 ring atoms (3- to 7 members), or 3- to 6 ring atoms (3- to 6 members), or 4- to 8 ring atoms (4- to 8 members), or 5- to 7 ring atoms (5- to 7 members). In some embodiments, it is advantageous to limit the number and type of ring heteroatoms in "heterocycloalkyl" or "heterocycloalkylene" to a specific range or type of heteroatoms, such as 1 to 5 ring heteroatoms selected from nitrogen, oxygen and sulfur. Polycyclic ring systems include fused, bridged and spiral systems. The ring structure may optionally contain an oxo group on a carbon ring member or up to two oxo groups on a sulfur ring member. Illustrative examples of heterocycloalkyl groups include monovalent groups of the following entities, while heterocycloalkylene groups include divalent groups of the following entities, which are in the form of properly bound moieties:

[0168]

[0169] The three-membered heterocyclic ring may contain at least one heteroatom ring atom, wherein the heteroatom ring atom is sulfur, oxygen or nitrogen. Non-limiting examples of three-membered heterocyclic groups include the monovalent and divalent groups of oxirane, azetidine and thiirane. The four-membered heterocyclic ring may contain at least one heteroatom ring atom, wherein the heteroatom ring atom is sulfur, oxygen or nitrogen. Non-limiting examples of four-membered heterocyclic groups include the monovalent and divalent groups of azetidine, oxetane and thiirane. The five-membered heterocyclic ring may contain up to four heteroatom ring atoms, wherein (a) at least one ring atom is oxygen and sulfur, and zero, one, two or three ring atoms are nitrogen, or (b) zero ring atoms are oxygen or sulfur, and up to four ring atoms are nitrogen. Non-limiting examples of five-membered heterocyclic groups include monovalent and divalent radicals of pyrrolidine, tetrahydrofuran, 2,5-dihydro-1H-pyrrole, pyrazolidine, thiazolidine, 4,5-dihydro-1H-imidazole, dihydrothiophen-2(3H)-one, tetrahydrothiophene 1,1-dioxide, imidazolidin-2-one, pyrrolidin-2-one, dihydrofuran-2(3H)-one, 1,3-dioxolan-2-one, and oxazolidin-2-one. Six-membered heterocyclic rings may contain up to four heteroatom ring atoms, wherein (a) at least one ring atom is oxygen and sulfur, and zero, one, two, or three ring atoms are nitrogen, or (b) zero ring atoms are oxygen or sulfur, and up to four ring atoms are nitrogen. Non-limiting examples of six-membered heterocyclic groups include monovalent or divalent groups of piperidine, morpholine, 4H-1,4-thiazine, 1,2,3,4-tetrahydropyridine, piperazine, 1,3-oxazinan-2-one, piperazin-2-one, thiomorpholine, and thiomorpholine 1,1-dioxide. "Heterobicyclic" is a fused bicyclic ring system comprising a heterocycle fused to a cycloalkyl or another heterocycle.

[0170] It should be understood that, as described herein, a heterocycloalkyl or heterocycloalkylene group may be unsubstituted or substituted. A heterocycloalkyl or heterocycloalkylene group may be substituted with any substituent in the various embodiments described herein, including one or more of such substituents.

[0171] The term "heteroaryl" refers to a monovalent monocyclic, fused bicyclic or fused polycyclic aromatic heterocyclic ring (ring structure having ring atoms or members selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen and sulfur) which is fully unsaturated and each heterocyclic ring has 3 to 12 ring atoms. The term "heteroarylene" refers to a divalent monocyclic, fused bicyclic or fused polycyclic aromatic heterocyclic ring (ring structure having ring atoms or members selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen and sulfur) which each heterocyclic ring has 3 to 12 ring atoms. In some embodiments, it may be advantageous to limit the number of ring atoms in "heteroaryl" or "heteroarylene" to a specific range of atomic members, such as a 5- to 10-membered heteroaryl or a 5- to 10-membered heteroarylene. In some cases, a 5- to 10-membered heteroaryl may be a monocyclic or fused bicyclic ring having 5- to 10 ring atoms, wherein at least one ring atom is a heteroatom, such as N, O or S. In some cases, the 5- to 10-membered heteroarylene group may be a monocyclic or fused bicyclic ring having 5- to 10 ring atoms, wherein at least one ring atom is a heteroatom, such as N, O, or S. Illustrative examples of 5- to 10-membered heteroarylene groups include monovalent groups of the following entities, while examples of 5- to 10-membered heteroarylene groups include divalent groups of the following entities, in the form of appropriately bonded moieties:

[0172]

[0173] In some embodiments, "monocyclic" heteroaryl can be an aromatic five- or six-membered heterocycle. A five-membered heteroaryl or sub-heteroaryl can contain up to four heteroatom ring atoms, wherein (a) at least one ring atom is oxygen and sulfur and zero, one, two or three ring atoms are nitrogen, or (b) zero ring atoms are oxygen or sulfur and up to four ring atoms are nitrogen. Non-limiting examples of five-membered heteroaryl include monovalent groups of furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, pyrazole, imidazole, oxadiazole, thiadiazole, triazole or tetrazole. Non-limiting examples of five-membered sub-heteroaryl include divalent groups of furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, pyrazole, imidazole, oxadiazole, thiadiazole, triazole or tetrazole. Six-membered heteroaryl or heteroarylidene may contain up to four heteroatom ring atoms, wherein (a) at least one ring atom is oxygen and sulfur and zero, one, two or three ring atoms are nitrogen, or (b) zero ring atoms are oxygen or sulfur and up to four ring atoms are nitrogen. Non-limiting examples of six-membered heteroaryl include monovalent groups of pyridine, pyrazine, pyrimidine, pyridazine or triazine. Non-limiting examples of six-membered heteroarylidene include divalent groups of pyridine, pyrazine, pyrimidine, pyridazine or triazine. "Bicyclic heteroaryl" or "bicyclic heteroarylidene" is a fused bicyclic ring system comprising a heteroaryl ring fused to phenyl or another heteroaryl ring. Non-limiting examples of bicyclic heteroaryl groups include monovalent radicals of quinoline, isoquinoline, quinazoline, quinoxaline, indole, 1,5-naphthyridine, 1,8-naphthyridine, isoquinolin-3(2H)-one, thieno[3,2-b]thiophene, 1H-pyrrolo[2,3-b]pyridine, 1H-benzo[d]imidazole, benzo[d]oxazole, and benzo[d]thiazole. Non-limiting examples of bicyclic heteroarylene groups include divalent radicals of quinoline, isoquinoline, quinazoline, quinoxaline, indole, 1,5-naphthyridine, 1,8-naphthyridine, isoquinolin-3(2H)-one, thieno[3,2-b]thiophene, 1H-pyrrolo[2,3-b]pyridine, 1H-benzo[d]imidazole, benzo[d]oxazole, and benzo[d]thiazole.

[0174] In particular, the pyrrolyl moiety may be represented by the structure In particular, the pyrrolyl moiety can be represented by the structural formula In particular, the pyrazolyl moiety can be represented by the structural formula In particular, the pyrazolyl moiety can be represented by the structural formula Describe.

[0175] It should be understood that, as described herein, a heteroaryl or heteroarylene group can be unsubstituted or substituted. A heteroaryl or heteroarylene group can be substituted with any substituent in the various embodiments described herein, including one or more of such substituents.

[0176] The term "oxo" refers to a carbonyl oxygen. For example, an oxo-substituted cyclopentyl is cyclopentanone.

[0177] Certain chemical entities of formula (I) to (XII) can be depicted in two or more tautomeric forms. Any and all alternative tautomers are included within the scope of these formulas, and it should not be inferred whether the chemical entity exists in the tautomeric form it is drawn. It should be understood that the chemical entities described herein and their constituent rings A, B, etc. can exist in different tautomeric forms. Those skilled in the art will readily appreciate that due to rapid interconversion, tautomers can generally be considered to be the same chemical compound. Examples of tautomers include, but are not limited to, enol-keto tautomers, amine-imine tautomers, etc.

[0178]

[0179] In particular, the ring selection of the indolin-2-one subunit can exist as the following tautomers

[0180]

[0181] The term "substituted" means that the specified group or part has one or more substituents. The term "unsubstituted" means that the specified group has no substituents. In the case where the term "substituted" is used to describe a structural system, the substitution is intended to occur at any valence-allowed position on the system. In some embodiments, "substituted" means that the specified group or part has one, two or three substituents. In other embodiments, "substituted" means that the specified group or part has one or two substituents. In yet other embodiments, "substituted" means that the specified group or part has one substituent.

[0182] Any formula depicted herein is intended to represent the compound of the formula as well as certain variations or forms. For example, the formula given herein is intended to include racemic forms, or one or more enantiomers, diastereomers or geometric isomers or mixtures thereof. In addition, any formula given herein is intended to also refer to hydrates, solvates or polymorphs of such a compound or mixtures thereof.

[0183] Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced with atoms having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P.32 P. 35 S. 18 F. 36 Cl and 125 I. Such isotopically labeled compounds are suitable for metabolic studies (preferably using 14 C), reaction kinetics studies (using e.g. 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single photon emission computed tomography (SPECT)], including drug or substrate tissue distribution analysis, or radiotherapy of patients. In addition, the use of heavier isotopes such as deuterium (i.e. 2 H) may provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the reaction schemes or examples and the preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0184] Nomenclature" (ATOM) i-j "(wherein j>i) when applied herein to a class of substituents is intended to refer to embodiments of the invention in which each of the numbers of atom members from i to j (including i and j) is independently realized. For example, the term C 1-3 Independently refers to the embodiment with one carbon member (C1), the embodiment with two carbon members (C2), and the embodiment with three carbon members (C3).

[0185] Any reference to a disubstituent herein is intended to encompass a variety of attachment possibilities when more than one such possibility is permitted. For example, reference to a disubstituent -AB- (where A≠B) herein refers to such a disubstituent having A attached to the first substituted member and B attached to the second substituted member, and it also refers to such a substituent having A attached to the second substituted member and B attached to the first substituted member. For example, in certain embodiments, where applicable, a compound moiety -(L) having the formula -CH2OCH2(C(CH3)H)- connecting two groups A and B n - should be understood as -CH2OCH2(C(CH3)H)- can include both embodiments A-CH2OCH2(C(CH3)H)-B and B-CH2OCH2(C(CH3)H)-A. More particularly in the present case, having a linking group -B- and -NR 9 -The compound part of the formula -CH2OCH2(C(CH3)H)- –(L) n - compounds of formula (I) to (XII) are understood to include Example B -CH2OCH2(C(CH3)H)-NR9 and-NR 9 -CH2OCH2(C(CH3)H)-B both.

[0186] The present invention also includes pharmaceutically acceptable salts of compounds represented by Formulae (I) through (XII), preferably those described above and the specific compounds listed herein, and pharmaceutical compositions comprising such salts, and methods of using such salts.

[0187] "Pharmaceutically acceptable salts" are intended to mean salts of the free acids or bases of the compounds represented herein that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to a subject. See, generally, SM Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66, 1-19. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of a subject without undue toxicity, irritation, or allergic response. The compounds described herein may have sufficiently acidic groups, sufficiently basic groups, both types of functional groups, or more than one of each type, and therefore react with a variety of inorganic or organic bases and inorganic and organic acids to form pharmaceutically acceptable salts.

[0188] Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, hexanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1, The pharmaceutically acceptable salts of the present invention are hydroxybenzoate, hydroxybenzoate, methylbenzoate, methylbenzenesulfon ...

[0189] For compounds of formula (I) to (XII) containing a basic nitrogen, pharmaceutically acceptable salts can be prepared by any suitable method available in the art, for example, by reacting the free base with an inorganic acid (such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, etc.) or with an organic acid (such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, etc.) acid), succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidic acid such as glucuronic acid or galacturonic acid, an α-hydroxy acid such as mandelic acid, citric acid or tartaric acid, an amino acid such as aspartic acid or glutamic acid, an aromatic acid such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid or cinnamic acid, a sulfonic acid such as lauryl sulfonic acid, p-toluenesulfonic acid, methanesulfonic acid or ethanesulfonic acid, or any compatible mixture of acids such as those given by way of example herein, and any other acids and mixtures thereof which are regarded as equivalents or acceptable substitutes in view of the ordinary level of skill in the art.

[0190] The present invention also relates to pharmaceutically acceptable prodrugs of compounds of formula (I) to (XII) and methods of treatment using such pharmaceutically acceptable prodrugs. The term "prodrug" refers to a precursor of a specified compound that, after administration to a subject, produces the compound in vivo via a chemical or physiological process (such as solvolysis or enzymatic cleavage) or under physiological conditions (e.g., the prodrug is converted to a compound of formula (I) to (XII) when physiological pH is reached). A "pharmaceutically acceptable prodrug" is a prodrug that is non-toxic, biologically tolerable, and or biologically suitable for administration to a subject. Exemplary procedures for selecting and preparing suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

[0191] The present invention also relates to pharmaceutically active metabolites of compounds of formula (I) to (XII) and the use of such metabolites in the methods of the present invention. "Pharmaceutically active metabolite" means a pharmaceutically active product of the metabolism of a compound of formula (I) to (XII) or a salt thereof in vivo. Prodrugs and active metabolites of a compound can be determined using conventional techniques known or available in the art. See, e.g., Bertolini et al., J. Med. Chem. 1997, 40, 2011-2016; Shan et al., J. Pharm. Sci. 1997, 86(7), 765-767; Bagshawe, Drug Dev. Res. 1995, 34, 220-230; Bodor, Adv. Drug Res. 1984, 13, 255-331; Bundgaard, Design of Prodrugs (Elsevier Press, 1985); and Larsen, Design and Application of Prodrugs, Drug Design and Development. and Development) (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991).

[0192] As used herein, the term "protecting group" or "PG" refers to any group generally known to those of ordinary skill in the art that can be introduced into a molecule by chemically modifying a functional group (such as an amine or hydroxyl group) to obtain chemical selectivity in a subsequent chemical reaction. It should be understood that such protecting groups can be subsequently removed from the functional group at a later point in the synthesis to provide further opportunity for reaction at such functional group or in the case of the final product to mask such functional group. Protecting groups have been described, for example, in Wuts, PGM, Greene, TW, Greene TW, and John Wiley & Sons. (2006). Greene's protective groups inorganic synthesis. Hoboken, NJ: Wiley International Publishing Group. It will be readily apparent to those skilled in the art that such protecting groups can be installed on the functional group to chemical processing conditions. Suitable amine protecting groups suitable for incorporation into the present invention include, but are not limited to, 9-fluorenylmethylcarbonyl (FMOC), tert-butylcarbonyl (Boc), benzyloxycarbonyl (Cbz), acetyl (Ac), trifluoroacetyl, phthalimide, benzyl (Bn), triphenylmethyl (trityl, Tr), benzylidene, and p-toluenesulfonyl (toluenesulfonamide, Ts).

[0193] Representative Examples

[0194] In some embodiments, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof,

[0195]

[0196] Among them, A, B, L, R 6 , R 7 , R 8 , R 9 , Y, Y 1 and n are as described herein.

[0197] In some embodiments, the present invention provides a compound of formula II or a pharmaceutically acceptable salt thereof,

[0198]

[0199] Among them, A, B, L, R 7 , R 8 , R 9 and n are as described herein.

[0200] In some embodiments, the present invention provides a compound of formula III or a pharmaceutically acceptable salt thereof,

[0201]

[0202] Among them, B, L, R 1 , R 1a , R 7 , R 8 , R 9 and n are as described herein.

[0203] In some embodiments, the present invention provides a compound of formula IV or a pharmaceutically acceptable salt thereof,

[0204]

[0205] Among them, B, L, R 1a , R 7 , R 8 , R 9 and n are as described herein.

[0206] In some embodiments, the present invention provides a compound of formula V or a pharmaceutically acceptable salt thereof,

[0207]

[0208] Among them, A, L, R 2 , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0209] In some embodiments, the present invention provides a compound of formula VI or a pharmaceutically acceptable salt thereof,

[0210]

[0211] Among them, A, L, R 2a , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0212] In some embodiments, the present invention provides a compound of formula VII or a pharmaceutically acceptable salt thereof,

[0213]

[0214] Among them, L, R 1 , R 1a , R 2 , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0215] In some embodiments, the present invention provides a compound of formula VIII or a pharmaceutically acceptable salt thereof,

[0216]

[0217] Among them, L, R 1 , R 2 , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0218] In some embodiments, the present invention provides a compound of formula IX or a pharmaceutically acceptable salt thereof,

[0219]

[0220] Among them, L, R 1 , R 1a , R 2a , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0221] In some embodiments, the present invention provides a compound of formula X or a pharmaceutically acceptable salt thereof,

[0222]

[0223]

[0224] Among them, L, R 1 , R 2a , R 2b , R 7 , R 8 , R 9 and n are as described herein.

[0225] In some embodiments, the present invention provides a compound of formula XI or a pharmaceutically acceptable salt thereof,

[0226]

[0227] Among them, L, R 1 , R 1a , R 2 , R 2b , R 7 and n are as described herein.

[0228] In some embodiments, the present invention provides a compound of Formula XII or a pharmaceutically acceptable salt thereof,

[0229]

[0230] Among them, L, R 1 , R 1a , R 2a , R 2b , R 7 and n are as described herein.

[0231] In some embodiments, Ring A is

[0232] In some embodiments, Ring B is

[0233] In some embodiments, Ring B is And R 7 is H. In some embodiments, Ring A is Ring B is And R 7 is H. In some embodiments, Ring B is And R 7 is not H. In some embodiments, Ring A is Ring B is And R 7 is not H. In some embodiments, Ring B is And R 7 is -Cl or -CN. In some embodiments, Ring A is Ring B is And R 7 is -Cl or -CN. In some embodiments, Ring B is And R 7 is -Cl. In some embodiments, Ring A is Ring B is And R 7 is -Cl. In some embodiments, Ring B is And R 7 is -CN. In some embodiments, Ring A is Ring B is And R 7 Yes – CN.

[0234] In some embodiments, R 1 are independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b 、-PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a, -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e Rf 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0235] In some embodiments, R 1 is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NRe R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e In some embodiments, R 1 It is H, -CN or methyl.

[0236] In some embodiments, R 1a is H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PRa R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)ORe 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0237] In some embodiments, R 1a is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NRe R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e In some embodiments, R 1a When present it is H, -CN or methyl.

[0238] In some embodiments, R 2 is H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR aS(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0239] In some embodiments, R 2 are independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0240] In some embodiments, R 2 is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e In some embodiments, R 2 It is H, -CN or methyl.

[0241] In some embodiments, R 2a is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0242] In some embodiments, R 2ais H or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR eIn some embodiments, R 2a It is H or methyl.

[0243] In some embodiments, R 2b is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl or 3- to 4-membered heterocycloalkyl, wherein each hydrogen atom in C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl and 3- to 4-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, -O(H or C1-C2 alkyl), -OC(O)C1-C2 alkyl, -OC(O)N(H or C1-C2 alkyl)2, -OS(O)C1-C2 alkyl, -OS(O)2C1 -C2 alkyl, -OS(O)N(H or C1-C2 alkyl)2, -OS(O)2N(H or C1-C2 alkyl)2, -S(H or C1-C2 alkyl), -S(O)C1-C2 alkyl, -S(O)2C1-C2 alkyl, -S(O)N(H or C1-C2 alkyl)2, -S(O)2N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)C(O)C1-C2 alkyl, -N(H or C1-C2 C(O)O(H or C1-C2 alkyl), -N(H or C1-C2 alkyl)C(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)2C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)2N(H or C1-C2 alkyl)2, -C(O)C1-C2 alkyl , -C(O)O(H or C1-C2 alkyl), -C(O)N(H or C1-C2 alkyl)2, -P(H or C1-C2 alkyl)2, -P(O)(H or C1-C2 alkyl)2, -P(O)2(H or C1-C2 alkyl)2, -P(O)N(H or C1-C2 alkyl)2, -P(O)2N(H or C1-C2 alkyl)2, -P(O)O(H or C1-C2 alkyl), -P(O)2O(H or C1-C2 alkyl), -CN or -NO2.

[0244] In some embodiments, R 2b is C1-C4 alkyl or C3-C4 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl and C3-C4 cycloalkyl is independently optionally substituted with deuterium or halogen. 2b It is methyl, ethyl, isopropyl or cyclopropyl.

[0245] In some embodiments, each L is independently -C(R 3 )(R4 )-、-C(O)-、-O-、-N(R 5 )-, -S-, -S(O)- or -S(O)2-, with the restriction (L) n Does not include –OO-, –OS-, –SS-, or –ON(R 5 In some embodiments, each L is independently -C(R 3 )(R 4 )-, -C(O)-, -O-, -S-, -S(O)- or -S(O)2-, with the restriction that (L) n does not contain -OO-, -SS-, or -OS- bonds. In some embodiments, L does not contain -N(R 5 )-.

[0246] In some embodiments, each R 3 and R 4 are independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR c 、-OC(O)R c 、-OC(O)NR c R d 、-OC(=N)NR c R d 、-OS(O)R c 、-OS(O)2R c 、-OS(O)NR c R d 、-OS(O)2NR c R d 、-SR c 、-S(O)R c 、-S(O)2R c 、-S(O)NR c R d 、-S(O)2NR c R d 、-NR c R d 、-NR c C(O)R d 、-N(C(O)R c )(C(O)R d ),-NR c C(O)OR d 、-NR c C(O)NR c R d 、-NR cC(=N)NR c R d 、-NR c S(O)R d 、-NR c S(O)2R d 、-NR c S(O)NR c R d 、-NR c S(O)2NR c R d 、-C(O)R c 、-C(O)OR c 、-C(O)NR c R d 、-C(=N)NR c R d , -PR c R d 、-P(O)R c R d 、-P(O)2R c R d 、-P(O)NR c R d 、-P(O)2NR c R d 、-P(O)OR c 、-P(O)2OR c , -CN, -NO2, or R 3 , R 4 and R 5 The two of them and the atoms to which they are connected together form a C3-C6 cycloalkyl or a 4- to 8-membered heterocycloalkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e Rf 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0247] In some embodiments, each L is independently selected from the group consisting of -C(O)-, -O-, -CH2-, -C(H)(CH3)-, -C(H)(OH)-, -NH-, and -NCH3-. In some embodiments, -(L) n-is-(CH2)2-,-(CH2)3-,-(CH2)4-,-(CH2)5-,-(CH2)6-,-C(O)NH-(CH2)2O(CH2)2-,-C(O)N(CH3)-(CH2)2O(CH2)2-,-NHC(O)CH2O(CH2)2-,-N(CH3)-C(O)CH2O(CH2)2-,-CH2O(CH2)2-,-CH2O(CH2)3-,-CH2O(C(CH3)H)2-,-(CH2)2O(CH2)2-,-CH2OCH2(C(CH3)H)-,-(CH2)2O(CH2)2-,-CH2OCH2(C(CH3)H)-,-(CH2)2OCH2(C(CH3)H)-,-(CH2)2OCH2(C(CH3)H)-,-(CH2 )2S(CH2)2-、-O(CH2)2S(CH2)2-、-(CH2)2SO2(CH2)2-、-O(CH2)2SO2(CH2)2-、-(CH2)2SO(CH2)2-、-O(CH2)2SO(CH2)2-、-(CH2)2O(C(H)(C(O)N(H) (CH3))-CH2-、-(CH2)2O(C(H)(C(O)N(CH3)2)-CH2-、-(CH2)2O(C(H)(C(O)OCH3)-CH2-、-(CH2)3O(CH2)2-、-(CH2)2O(CH2)3-、-CH2CH(CH3)-O(CH2) 2-、-CH(CH3)-CH2O(CH2)2-、-O(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)2CH(CH3)-、-OCH2O(CH2)2-、-O-CH2CH(OH)CH2-、-O-(CH2)2O(CH2)2-、-O-CH2CH(CH3)-O(CH2)2-、-O-CH(CH3)-CH2O(CH2)2-、-O-(CH2)2NH-(CH2)2-、-O-CH2CH(CH3)-NH-(CH2)2-、-O-CH(CH3)-CH2NH-(CH2)2-、-O-CH(CH3)-CH2NH-(CH2)2-、-CH2NH -(CH2)2-、-(CH2)2NH-(CH2)2-、-CH2CH(CH3)-NH-(CH2)2-、-CH(CH3)-CH2NH-(CH2)2-、-O-(CH2)2N(CH3)-(CH2)2-、-O-CH2CH(CH3)-N(CH3)-(CH2) )2-、-O-CH(CH3)-CH2N(CH3)-(CH2)2-、-CH2N(CH3)-(CH2)2-、-CH2N(CH2CH3)-(CH2)2-、-CH2N((CH2)2CH3)-(CH2)2-、-CH2N(CH(CH3)2)-(CH2)2-、-(CH2)2N(CH3)-(CH2)2-, -CH2CH(CH3)-N(CH3)-(CH2)2-, or -O-CH(CH3)-CH2N(CH3)-(CH2)2-. In some embodiments, -Z-(L), n -Z 1 - does not contain –OO-, -OS- or –ON(R x )- bond. In some embodiments, -(L) n - is -O(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -CH2OCH2(C(CH3)(H))-, -CH2O(CH2)2- or -CH2O(CH2)3-. In some embodiments, -(L) n - is -O(CH2)3-, -CH2OCH2(C(CH3)(H))- or -CH2O(CH2)2-.

[0248] In some embodiments, R 1a , R 2a , R 5 , R 8 and R 9 Each independently is H or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)Rf 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e In some embodiments, R 1a is H or methyl. In some embodiments, R 2a is H or methyl. In some embodiments, R 5 is H or methyl. In some embodiments, R 8 is H or methyl. In some embodiments, R 9 It is H or methyl.

[0249] In some embodiments, R 6 and R 7 Each of the above is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NRa R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2; or R 6 and R 7 Together with the carbon to which it is attached, it forms a C4-C6 cycloalkyl, a 4- to 7-membered heterocycloalkyl or a C6-C 10 Aryl, among which C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2Re 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2.

[0250] In some embodiments, R 6 is H, deuterium, fluorine, chlorine, -CN or C1-C6 alkyl, such as methyl or ethyl. In some embodiments, R 7 is H, deuterium, fluorine, chlorine, -CN or C1-C6 alkyl, such as methyl or ethyl. In some embodiments, R 6 is H or deuterium, and R7 is deuterium, fluorine, chlorine, -CN or C1-C6 alkyl, such as methyl or ethyl. In some embodiments, R 7 is H. In some embodiments, R 7 In some embodiments, R 7 is a C1-C6 alkyl group, such as a methyl group or an ethyl group. 7 In some embodiments, R 7 is -Cl. In some embodiments, R 7 Yes-CN.

[0251] In some embodiments, n is 2, 3, 4, 5, 6, 7, or 8. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8.

[0252] In some embodiments, the present invention provides a compound selected from the group consisting of: [3a(4)Z]-6,9,15,16-tetramethyl-9,10,11,12-tetrahydro-15H-1,17-(ethylenediyl)pyrazolo[4,3-n]dipyrrolo[3,2-g:3',4'-j][1,5]oxazacyclopentadecen-3,8(2H,5H)-dione;

[0253] [3a(4)Z]-6,9,15,16-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0254] [3a(4)Z,10R]-20-chloro-6,10,15-trimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0255] [3a(4)Z,10R]-20-chloro-10,15-dimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0256] [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0257] [3a(4)Z,10S]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0258] [3a(4)Z]-20-chloro-6,9,15-trimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0259] [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-f]pyrazolo[4,3-m]pyrrolo[3,4-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0260] [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,16-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0261] [3a(4)Z,10R]-6,9,10,15-tetramethyl-3,8-dioxo-3,5,8,9,10,11,13,15-octahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-20-carbonitrile;

[0262] [3a(4)Z,10R]-20-fluoro-6,9,10,15,16-pentamethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0263] [3a(4)Z,10R]-20-chloro-6,9,10,15,16-pentamethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; and

[0264] [3a(4)Z,10R]-20-fluoro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione;

[0265] or a pharmaceutically acceptable salt thereof.

[0266] The following represent exemplary embodiments of compounds of formula (I):

[0267]

[0268]

[0269]

[0270] and pharmaceutically acceptable salts thereof.

[0271] One skilled in the art will recognize that the species listed or described herein are not exhaustive and that additional species within the scope of these defined terms may also be selected.

[0272] Pharmaceutical composition

[0273] For therapeutic purposes, pharmaceutical compositions comprising compounds described herein may further comprise one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients are non-toxic and or biologically suitable substances for administration to subjects. Such excipients are conducive to administering compounds described herein and are compatible with active ingredients. Examples of pharmaceutically acceptable excipients include stabilizers, lubricants, surfactants, diluents, antioxidants, adhesives, colorants, bulking agents, emulsifiers or taste improvers. In a preferred embodiment, the pharmaceutical composition according to the present invention is a sterile composition. Pharmaceutical compositions can be prepared using compounding techniques known or available to those skilled in the art.

[0274] The present invention also encompasses sterile compositions, including compositions that comply with national and local regulations governing such compositions.

[0275] The pharmaceutical compositions and compounds described herein can be formulated as solutions, emulsions, suspensions or dispersions, pills, tablets, lozenges, suppositories, sachets, lozenges, granules, powders, powders for rehydration, or capsules and solid carriers in suitable pharmaceutical solvents or carriers according to conventional methods known in the art for preparing various dosage forms. The pharmaceutical compositions of the present invention can be administered by suitable delivery routes, such as oral, parenteral, rectal, nasal, topical, or ocular routes or by inhalation. Preferably, the composition is formulated for intravenous or oral administration.

[0276] For oral administration, the compounds of the present invention can be provided in solid form (such as tablets or capsules), or in solution, emulsion or suspension. In order to prepare oral compositions, the compounds of the present invention can be formulated to produce, for example, a dose of about 0.1 mg to 1 g per day, or about 1 mg to 50 mg per day, or about 50 to 250 mg per day, or about 250 mg to 1 g per day. Oral tablets may include active ingredients mixed with compatible pharmaceutically acceptable excipients (such as diluents, disintegrants, binders, lubricants, sweeteners, flavoring agents, colorants and preservatives). Suitable inert fillers include sodium carbonate and calcium carbonate, sodium phosphate and calcium phosphate, lactose, starch, sugar, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, etc. Illustrative liquid oral excipients include ethanol, glycerol, water, etc. Starch, polyvinyl pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose and alginic acid are illustrative disintegrants. Binders may include starch and gelatin. The lubricant, when present, may be magnesium stearate, stearic acid or talc.If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be provided with an enteric coating.

[0277] Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, the active ingredient can be mixed with a solid, semisolid or liquid diluent. Soft gelatin capsules can be prepared by mixing the active ingredient with water, oil (such as peanut oil or olive oil), liquid paraffin, a mixture of mono- and di-glycerides of short-chain fatty acids, polyethylene glycol 400 or propylene glycol.

[0278] Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups, or may be lyophilized or presented as dry products for reconstitution with water or other suitable vehicles before use. Such liquid compositions may optionally contain: pharmaceutically acceptable excipients, such as suspending agents (e.g., sorbitol, methylcellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, etc.); non-aqueous vehicles, such as oils (e.g., almond oil or fractionated coconut oil), propylene glycol, ethanol or water; preservatives (e.g., methyl para-hydroxybenzoate or propyl para-hydroxybenzoate or sorbic acid); wetting agents, such as lecithin; and optional flavoring or coloring agents.

[0279] For parenteral administration (including intravenous, intramuscular, intraperitoneal, intranasal or subcutaneous routes), the medicament of the present invention can be provided in a sterile aqueous solution or suspension, buffered to a suitable pH and isotonicity or contained in a parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms can be presented in single-dose form, such as an ampoule or a disposable injection device; in multiple-dose form, such as a vial from which a suitable dose can be drawn; or in a solid form or preconcentrate that can be used to prepare an injectable formulation. Exemplary infusion doses are in the range of about 1 to 1000 μg / kg / minute of the medicament mixed with a pharmaceutical carrier over a period of time ranging from a few minutes to a few days.

[0280] For nasal, inhaled or oral administration, the present pharmaceutical composition can be administered using, for example, a spray formulation also containing a suitable carrier. The present composition can be formulated for rectal administration as a suppository.

[0281] For topical application, the compounds of the present invention are preferably formulated as a cream or ointment or similar vehicle suitable for topical administration. For topical administration, the compounds can be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of the drug to the vehicle. Another mode of administering the medicament of the present invention can use a patch formulation to achieve transdermal delivery.

[0282] As used herein, the terms "treat" or "treatment" encompass both "preventative" and "therapeutic (curative)" treatments. "Preventative" treatments are intended to indicate delaying the development of a disease, symptom of a disease, or medical condition, inhibiting symptoms that may occur, or reducing the risk of development or recurrence of a disease or symptom. "Curing" treatments include reducing the severity of an existing disease, symptom, or condition or inhibiting the deterioration of an existing disease, symptom, or condition. Thus, treatment includes improving or preventing the deterioration of existing disease symptoms, preventing additional symptoms from occurring, improving or preventing the underlying systemic cause of a symptom, inhibiting a disorder or disease, e.g., curbing the development of a disorder or disease, alleviating a disorder or disease, causing regression of a disorder or disease, alleviating a condition caused by a disease or condition, or stopping the symptoms of a disease or condition.

[0283] The term "subject" refers to a mammalian patient, such as a human, in need of such treatment.

[0284] Illustrative diseases include autoimmune diseases and inflammation. Autoimmune diseases include, for example, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and systemic lupus erythematosus, Sjogren syndrome, type I diabetes, and lupus. Illustrative neurological diseases include Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, and Huntington's disease. Illustrative inflammatory diseases include atherosclerosis, allergies, and inflammation from infection or injury.

[0285] In one aspect, the compounds and pharmaceutical compositions of the present invention specifically target TYK2. Therefore, these compounds and pharmaceutical compositions can be used to prevent, reverse, slow or inhibit the activity of TYK2. In preferred embodiments, the treatment method targets autoimmune diseases. In other embodiments, the method is used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and systemic lupus erythematosus, Sjögren's syndrome, type I diabetes and lupus.

[0286] In the inhibition methods of the present invention, "effective amount" means an amount sufficient to inhibit the target protein. Measuring such target modulation can be performed by conventional analytical methods (such as those described below). Such modulation is suitable for a variety of settings, including in vitro analysis. In such methods, the cell is preferably an autoimmune disease cell with abnormal signaling due to upregulation of TYK2.

[0287] In the method of treatment according to the present invention, "effective amount" means an amount or dosage sufficient to generally bring the expected therapeutic benefit to the subject in need of such treatment. The effective amount or dosage of the compound of the present invention can be determined by conventional methods, such as modeling, dose escalation or clinical trials, considering conventional factors, such as the mode or approach of administration or drug delivery, the pharmacokinetics of the agent, the severity and process of infection, the health status, condition and body weight of the subject, and the judgment of the attending physician. Illustrative dosage is in the range of about 0.1 mg to 1 g per day, or about 1 mg to 50 mg per day, or about 50 to 250 mg per day, or about 250 mg to 1 g per day. The total dose can be given in single or divided dose units (e.g., BID, TID, QID).

[0288] Once the patient's disease improves, the dosage can be adjusted for prevention or maintenance therapy. For example, the dosage or frequency or both given can be reduced to the extent that the desired treatment or preventive effect is maintained as a function of the symptoms. Of course, if the symptoms have been alleviated to an appropriate degree, the treatment can be stopped. However, the patient may need long-term intermittent treatment at any recurrence of symptoms. The patient may also need long-term chronic treatment.

[0289] Drug combinations

[0290] The compounds of the present invention described herein may be combined with one or more additional active ingredients for use in pharmaceutical compositions or methods to treat the diseases and conditions described herein. Other additional active ingredients include other therapeutic agents or agents that mitigate the adverse effects of the desired disease target therapy. Such combinations can be used to increase efficacy, improve other disease symptoms, reduce one or more side effects, or reduce the required dose of the compounds of the present invention. The additional active ingredients may be administered with the compounds of the present invention in separate pharmaceutical compositions, or may be included in a single pharmaceutical composition with the compounds of the present invention. The additional active ingredients may be administered simultaneously with, before, or after the administration of the compounds of the present invention.

[0291] Combination agents include additional active ingredients, which are those known or found to be effective in treating the diseases and conditions described herein, including their active substances relative to another target associated with the disease. For example, the compositions and formulations of the present invention and the methods of treatment may further include other drugs or medicines, for example, other active agents suitable for treating or alleviating the target disease or related symptoms or conditions.

[0292] Chemical synthesis method

[0293] The following examples are provided to illustrate but not to limit the invention. One skilled in the art will recognize that the following synthetic reactions and reaction schemes may be modified to obtain other compounds of formula (I) to (XII) by selecting appropriate starting materials and reagents.

[0294] Abbreviations: Examples described herein use materials including, but not limited to, those described by the following abbreviations known to those skilled in the art:

[0295]

[0296]

[0297]

[0298]

[0299] Preparation of intermediate types A, B and C

[0300] Example 1: Preparation of N-[3-(4-bromo-1,5-dimethyl-pyrazol-3-yl)oxypropyl]-N-methyl-carbamic acid tert-butyl ester (A1)

[0301]

[0302] Step 1. At 0° C., tert-butyl N-amino-N-methyl-carbamate (9.22 g, 63.0 mmol, 1.06 eq) and EDCI (12.5 g, 65.4 mmol, 1.1 eq) were added to a solution of but-2-ynoic acid (5 g, 59.5 mmol, 1 eq), DMAP (726 mg, 5.95 mmol, 0.1 eq) in DCM (200 mL). The reaction mixture was stirred at 25° C. for 16 hours. The reaction mixture was concentrated in vacuo to give tert-butyl N-(but-2-butynylamino)-N-methyl-carbamate (5.5 g, 25.9 mmol, 43.5% yield) as a white oil. 1 H NMR (400MHz, CDCl3) δ = 7.75 (s, 1H), 3.11 (s, 3H), 1.95 (s, 3H), 1.44 (s, 9H).

[0303] Step 2. At 25 ° C, hydrogen chloride (4.84g, 133mmol, 4.75mL, 5.13eq) was added to a solution of N-(but-2-ynylamino)-N-methyl-t-butyl carbamate (5.5g, 25.9mmol, 1.00eq) in 2-propyl alcohol (60mL), and the mixture was stirred for 16 hours at 63 ° C under N2. The reaction mixture was cooled to ambient temperature and concentrated in a vacuum. Then CH3CN (50mL, 10mL / g) was loaded into the resulting residue and concentrated in a vacuum. This process was repeated three times. Then, CH3CN (20mL, 4mL / g) was loaded into the final residue and heated to 75 ° C for 16 hours. Then the resulting slurries were cooled to ambient temperature in 1 hour and allowed to continue to desaturate overnight. The solid was filtered, washed with CH 3 CN (2×20 mL), and then dried under vacuum at ambient temperature to give the salt 1,5-dimethylpyrazol-3-ol (5.5 g, 24.5 mmol, 94.6% yield) as a white crystalline solid. 1 H NMR (400MHz, DMSO-d6) δ = 10.98 (s, 1H), 5.64 (s, 3H), 3.64 (s, 3H), 2.22 (s, 3H).

[0304] Step 3. A mixture of 1,5-dimethylpyrazol-3-ol (800 mg, 7.13 mmol, 1 eq), N-(3-chloropropyl)-N-methyl-carbamic acid tert-butyl ester (1.63 g, 7.85 mmol, 1.1 eq), K2CO3 (1.48 g, 10.7 mmol, 1.5 eq) in DMF (35 mL). The mixture was stirred at 80°C for 16 hours. After cooling to 25°C, the mixture was diluted with water (10 mL) and extracted with EA (3×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE:EA=30:1 to 0:1) to give tert-butyl N-[3-(1,5-dimethylpyrazol-3-yl)oxypropyl]-N-methyl-carbamate (600 mg, 2.12 mmol, 29.6% yield) as a yellow oil. 1 HNMR (400MHz, DMSO-d6) δ = 5.41 (s, 1H), 3.97–3.93 (m, 2H), 3.52 (s, 3H), 3. 32–3.23(m,2H),2.76(s,3H),2.14(s,3H),1.84–1.80(m,2H),1.36(s,9H).

[0305] Step 4. At 25 ° C, under N2, NBS (376 mg, 2.12 mmol, 1 eq) was added to a solution of N-[3-(1,5-dimethylpyrazol-3-yl)oxypropyl]-N-methyl-tert-butyl carbamate (600 mg, 2.12 mmol, 1 eq) in ACN (10 mL) for 16 hours. The reaction mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE: EA = 25: 1 to 0: 1) to obtain N-[3-(4-bromo-1,5-dimethyl-pyrazol-3-yl)oxypropyl]-N-methyl-tert-butyl carbamate (550 mg, 1.49 mmol, 70.3% yield, 98% purity) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ = 4.07 (t, J = 6.4Hz, 2H), 3.61 (s, 3H), 3.28 (t, J = 6.8Hz, 2H), 2.77 (s, 3H), 2.16 (s, 3H), 1.87 (t, J = 6.4Hz, 2H), 1.36 (s, 9H).

[0306] Example 2: Preparation of N-[2-[(4-bromo-1,5-dimethyl-pyrazol-3-yl)methoxy]ethyl]-N-methyl-carbamic acid tert-butyl ester (A2)

[0307]

[0308] Step 1. NBS (15.9 g, 89.2 mmol, 1.5 eq) is added to a solution of 1,5-dimethylpyrazole-3-ethyl formate (10.0 g, 59.5 mmol, 1 eq) in DCE (150 mL). The mixture is stirred at 80 ° C for 16 hours. After completion, the mixture is concentrated in vacuo to obtain a crude product. The residue is purified by column chromatography (SiO2, petroleum ether / ethyl acetate=0% to 30%) to obtain 4-bromo-1,5-dimethyl-pyrazole-3-ethyl formate (7.00 g, 28.3 mmol, 47.7% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ = 4.43 (t, J = 7.2Hz, 2H), 3.90 (s, 3H), 2.31 (s, 3H), 1.41 (t, J = 7.2Hz, 3H).

[0309] Step 2. At 0°C, LiAlH4 (1.56 g, 41.19 mmol, 1.2 eq) was added to a solution of 4-bromo-1,5-dimethyl-pyrazole-3-carboxylic acid methyl ester (8.0 g, 34.33 mmol, 1 eq) in THF (100 mL). The mixture was stirred at 15°C for 3 hours. After completion, the mixture was quenched by H2O (30 mL) and extracted with EtOAc (20 mL * 3) and then the resulting organic layer was dried over anhydrous Na2SO4, filtered and then the filtrate was concentrated in vacuo to give (4-bromo-1,5-dimethyl-pyrazole-3-yl) methanol (4.3 g, 20.97 mmol, 61.09% yield) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ = 4.93 (t, J = 5.6Hz, 2H), 4.30-4.27 (m, 2H), 3.72 (s, 3H), 3.32 (s, 3H).

[0310] Step 3. At 0 ° C, PBr3 (5.68g, 21.0mmol, 1eq) was added dropwise to a solution of (4-bromo-1,5-dimethyl-pyrazol-3-yl)methanol (4.30g, 21.0mmol, 1eq) in DCM (40mL). The mixture was stirred at 0 to 25 ° C for 4 hours. After completion, the mixture was concentrated in vacuo. It was added with NaHCO3 solution to adjust the pH to 7, and then extracted with DCM (30mL×4). The combined organic phase was dried over anhydrous sodium sulfate, filtered and then concentrated to obtain a residue. The residue was purified by flash column chromatography (combi flash) (40g silica gel column, DCM / MeOH=0 to 20%) to obtain (3.70g, 13.8mmol, 65.9% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ = 4.51 (s, 3H), 3.80 (s, 3H), 2.50 (s, 3H).

[0311] Step 4. N-(2-hydroxyethyl)-N-methyl-carbamic acid tert-butyl ester (3.45 g, 19.7 mmol, 63.6 μL, 1.1 eq), TBAI (661 mg, 1.79 mmol, 0.1 eq) and KOH (3.02 g, 53.7 mmol, 3 eq) were added to a solution of 4-bromo-3-(bromomethyl)-1,5-dimethylpyrazole (4.80 g, 17.9 mmol, 1 eq) in THF (100 mL). The mixture was stirred at 25 ° C for 16 hours under N2. After completion, the mixture was concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 50% to 70%). N-[2-[(4-bromo-1,5-dimethylpyrazol-3-yl)methoxy]ethyl]-N-methyl-carbamic acid tert-butyl ester (5.6 g, 15.5 mmol, 86.3% yield) was obtained as a white solid. 1 H NMR (400MHz, CDCl3) δ = 4.43 (s, 2H), 3.78 (s, 3H), 3.60-3.55 (m, 2H), 3.38-3.35 (m, 2H), 2.23 (s, 3H), 1.44 (s, 3H), 1.42 (s, 9H).

[0312] Example 2a: Preparation of N-[(1R)-2-[(4-bromo-1,5-dimethylpyrazol-3-yl)methoxy]-1-methylethyl]-N-methyl-carbamic acid tert-butyl ester (A2a)

[0313]

[0314] Step 1. NaH (3.37 g, 84.2 mmol, 60% purity, 2 eq) was added to a solution of (4-bromo-1,5-dimethylpyrazol-3-yl)methanol (8.64 g, 42.1 mmol, 1 eq) in DMF (180 mL) at 0°C. The mixture was stirred at 25°C for 0.5 h, followed by the addition of (4R)-tert-butyl 4-methyl-2,2-dioxothiazole-3-carboxylate (15.0 g, 63.2 mmol, 1.5 eq) and stirred at 25°C for another 1 h. Upon completion, the mixture was quenched by H2O (400 mL), extracted with EtOAc (100 mL*3), dried over anhydrous Na2SO4, and then filtered. The filtrate was concentrated in vacuo and purified by flash silica gel chromatography (80 g silica gel column, MeOH in DCM from 0 to 10%) to give tert-butyl N-[(1R)-2-[(4-bromo-1,5-dimethylpyrazol-3-yl)methoxy]-1-methylethyl]carbamate (10.2 g, 28.1 mmol, 66% yield) as a pink solid. 1H NMR (400MHz, DMSO-d6) δ = 6.71 (d, J = 8.4Hz, 1H), 4.36-4.25 (m, 2H), 3.74 (s, 3H), 3.64 -3.50(m,1H),3.31-3.27(m,1H),3.19-3.11(m,1H),2.23-2.21(m,3H),1.36(s,9H),0.99(d,J=6.8Hz,3H).

[0315] Step 2. NaH (1.10 g, 27.6 mmol, 60% purity, 2 eq) was added to a solution of tert-butyl N-[(1R)-2-[(4-bromo-1,5-dimethylpyrazol-3-yl)methoxy]-1-methylethyl]carbamate (5.00 g, 13.8 mmol, 1 eq) in DMF (100 mL) at 0°C. The mixture was stirred at 0°C for 0.5 h, and then CH3I (2.94 g, 20.7 mmol, 1.29 mL, 1.5 eq) was added. The mixture was stirred at 25°C for 1 h. Upon completion, the mixture was quenched by H2O (50 mL) and then extracted with EtOAc (40 mL*3). The combined organic layers were dried over anhydrous Na2SO4, filtered, and the filtrate was concentrated in vacuo to give the crude product. The residue was purified by flash silica gel chromatography (40 g silica gel column, THF / PE, from 0 to 50%) to give tert-butyl N-[(1R)-2-[(4-bromo-1,5-dimethylpyrazol-3-yl)methoxy]-1-methylethyl]-N-methyl-carbamate (3.35 g, 8.90 mmol, 64% yield). LCMS: m / z 377.7 (M+1).

[0316] Example 3: Preparation of tert-butyl N-[(1R)-2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]-1-methylethyl]carbamate (A3)

[0317]

[0318] In step 4 A3 was prepared using a similar procedure to A2 starting from methyl 1-methylpyrazole-3-carboxylate and tert-butyl N-[(1R)-2-hydroxy-1-methylethyl]carbamate to carry out the alkylation reaction. 1 H NMR (400MHz, DMSO-d6) δ = 7.90 (s, 1H), 6.68-6.44 (m, 2H), 4.33 (d, J = 3.6Hz, 3H),3.80(s,3H),3.64-3.40(m,2H),1.38-1.36(m,9H),1.00-0.97(m,6H).

[0319] Example 4: Preparation of N-[(1R)-2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]-1-methylethyl]-N-methyl-carbamic acid tert-butyl ester (A4)

[0320]

[0321] NaH (1.21 g, 30.2 mmol, 60% purity, 3.0 eq) was added to a solution of tert-butyl N-[(1R)-2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]-1-methylethyl]carbamate (A3, 3.50 g, 10.05 mmol, 1.0 eq) in THF (40 mL) at 0°C. The mixture was stirred at 0°C for 0.5 hours. And then CH3I (2.14 g, 15.1 mmol, 939 μL, 1.5 eq) was added. The mixture was stirred at 25°C for 1.5 hours. The mixture was quenched with saturated NH4Cl (150 mL) and extracted with ethyl acetate (50 mL*3), the combined organic phases were dried over anhydrous sodium sulfate, filtered and then concentrated to give tert-butyl N-[(1R)-2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]-1-methylethyl]-N-methyl-carbamate (3.20 g, crude) as a colorless oil. LCMS m / z 385.9 (M+23).

[0322] Example 5: Preparation of N-[(1S)-2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]-1-methylethyl]-N-methyl-carbamic acid tert-butyl ester (A5)

[0323]

[0324] A5 was prepared using a similar procedure to A4. LCMS m / z 385.9 (M+23).

[0325] Example 6: Preparation of tert-butyl N-[2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]ethyl]-N-methylcarbamate (A6)

[0326]

[0327] A6 was prepared using a similar procedure to A2. LCMS m / z 371.9 (M+23).

[0328] Example 7: Preparation of N-[(1R)-2-[[5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methoxy]-1-methylethyl]-N-methyl-carbamic acid tert-butyl ester (A7)

[0329]

[0330] Step 1. SEM-Cl (9.84 g, 59.0 mmol, 10.5 mL, 1.3 eq) was added to a mixture of 2-methyl-1H-imidazole-4-carbaldehyde (5.00 g, 45.4 mmol, 1 eq) in DCM (50.0 mL) at 0° C., followed by DIEA (7.63 g, 59.0 mmol, 10.2 mL, 1.3 eq) and DMAP (277 mg, 2.27 mmol, 0.05 eq), and the mixture was stirred for 0.5 h at 25° C. under N2. The reaction mixture was quenched by the addition of MeOH (50 mL) to give 2-methyl-1-(2-trimethylsilylethoxymethyl)imidazole-4-carbaldehyde (5.00 g, 20.8 mmol, 45.8% yield) as a yellow oil.

[0331] Step 2. At 0°C, NaBH4 (825 mg, 21.8 mmol, 1.05 eq) was added to a mixture of 2-methyl-1-(2-trimethylsilylethoxymethyl)imidazole-4-carboxaldehyde (5.00 g, 20.8 mmol, 1 eq) in MeOH (50.0 mL). Under N2, at 25°C, the mixture was stirred for 0.5 hours and then quenched by adding water (20.0 mL), followed by extraction with EtOAc (20.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and then concentrated under reduced pressure to give a crude residue. The residue was purified by flash silica gel chromatography ( 40.0g Sepa The product was purified by silica gel flash column, eluent 0 to 6% ethyl acetate / petroleum ether gradient at 50 mL / min) to give [2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methanol (5.00 g, 18.46 mmol, 88.76% yield, 89.5% purity) as a yellow oil. LCMS m / z 243.3 (M+1).

[0332] Step 3. At 0°C, NBS (4.41 g, 24.7 mmol, 1.2 eq) was added to a mixture of [2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methanol (5.00 g, 20.6 mmol, 1 eq) in ACN (50.0 mL). Under N2, at 25°C, the mixture was stirred for 1 hour and then partitioned between EtOAc (20.0 mL) and H2O (20.0 mL). The organic phase was separated, washed with brine (10.0 mL*3), dried over Na2SO4, filtered and then concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography ( 20g Sepa The product was purified by silica flash column (Silica Flash Column, 0 to 20% ethyl acetate / petroleum ether gradient eluent at 60 mL / min) to give [5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methanol (5.00 g, 14.78 mmol, 71.67% yield, 95.0% purity) as a yellow oil. LCMS m / z 323.1 (M+1).

[0333] Step 4. At 0°C, NaH (93.3 mg, 2.33 mmol, 60% purity, 1.5 eq) was added to a mixture of [5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)-imidazol-4-yl]methanol (500 mg, 1.56 mmol, 1 eq) in THF (10.0 mL). The mixture was stirred at 0°C for 0.5 hours. Then (4R)-4-methyl-2,2-dioxooxathiazolyl-3-carboxylic acid tert-butyl ester (443 mg, 1.87 mmol, 1.2 eq) was added and the mixture was stirred at 25°C for 1.5 hours. The reaction mixture was quenched by adding H2O (5.00 mL). The filtrate was diluted with H2O (5.00 mL) and extracted with EtOAc (5.00 mL*3). The combined organic layers were washed with brine (5 mL*3), dried over Na2SO4, filtered and then concentrated under reduced pressure. The residue was purified by preparative-TLC (SiO 2 , petroleum ether:ethyl acetate=0:1) to give tert-butyl N-[(1R)-2-[[5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methoxy]-1-methylethyl]carbamate (600 mg, 1.17 mmol, 75.1% yield) as a yellow oil. LCMS 479.5 (M+1).

[0334] Step 5. At 0°C, NaH (75.2 mg, 1.88 mmol, 60% purity, 1.5 eq) was added to a mixture of tert-butyl N-[(1R)-2-[[5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methoxy]-1-methylethyl]carbamate (600 mg, 1.25 mmol, 1 eq) in THF (7.00 mL), and the mixture was stirred for 0.5 hours at 0°C. Then CH3I (267 mg, 1.88 mmol, 117 μL, 1.5 eq) was added, and the mixture was stirred for 1.5 hours at 25°C. The reaction mixture was quenched by adding H2O (5.00 mL) at 25°C. The filter liquor was diluted with H2O (5.00 mL) and extracted with EtOAc (5.00 mL*3). The combined organic layers were washed with brine (5.00 mL*3), dried over Na2SO4, filtered and then concentrated under reduced pressure to give tert-butyl N-[(1R)-2-[[5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methoxy]-1-methylethyl]-N-methyl-carbamate (550 mg) as a yellow oil. LCMS 494.1 (M+1: 494.1).

[0335] Example 8: Preparation of [3-[[(2R)-2-[tert-butoxycarbonyl(methyl)amino]propoxy]methyl]-1-methylpyrazol-4-yl]boronic acid (B1)

[0336]

[0337] n-BuLi (2.5M, 5.52mL, 2.5eq) was added to a solution of tert-butyl N-[(1R)-2-[(4-bromo-1-methylpyrazol-3-yl)methoxy]-1-methylethyl]-N-methylcarbamate (2.00g, 5.52mmol, 1.0eq) in THF (20mL). The mixture was stirred at -70°C for 1 hour and then 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.08g, 16.6mmol, 3.38mL, 3.0eq) was added at -70°C. The mixture was stirred at -70°C for 3 hours. The mixture was quenched with water (50 mL) and extracted with ethyl acetate (25 mL×3), and the combined aqueous phases were dried over anhydrous sodium sulfate, filtered and concentrated to give [3-[[(2R)-2-[tert-butoxycarbonyl(methyl)amino]propoxy]methyl]-1-methylpyrazol-4-yl]boronic acid (1.75 g, crude) as a white solid. LCMS m / z 327.7 (M+1).

[0338] Example 8b: Preparation of 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one (D1)

[0339]

[0340] Step 1. At 0°C, NBS (12.9 g, 72.7 mmol, 1.1 eq) was added to a solution of 7-fluoroindolin-2-one (10.0 g, 66.1 mmol, 1 eq) in TFA (100 mL) and stirred for 0.5 hours. The mixture was stirred at 25°C for 6 hours. After completion, the reaction mixture was concentrated under reduced pressure to remove the solvent. At 20°C, the crude product was ground together with DCM:PE=(1:1, 400 mL) for 5 minutes to obtain 5-bromo-7-fluoroindolin-2-one (15.4 g, 59.7 mmol, 90% yield) as a brown solid. 1 HNMR (400MHz, DMSO-d6) δ = 11.05 (s, 1H), 7.41 (dd, J = 9.6Hz, 1H), 7.27 (s, 1H), 3.58 (s, 2H).

[0341] Step 2. Potassium acetate (28.7 g, 292 mmol, 4 eq) and cyclopentyl (diphenyl) phosphane; dichloromethane; dichloropalladium; iron (5.98 g, 7.32 mmol, 0.1 eq) were added to a solution of 5-bromo-7-fluoro-indolin-2-one (16.8 g, 73.2 mmol, 1 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (55.8 g, 219 mmol, 3 eq) in dioxane (250 mL). The mixture was stirred at 100 ° C for 16 hours under N2. After completion, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by flash silica gel chromatography ( 220g Sepa The product was purified by silica gel flash column, 0 to 20% MeOH / DCM eluent @ 40 mL / min to afford 7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one (14.3 g, 42.9 mmol, 58% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ = 11.01 (s, 1H), 7.32 (s, 1H), 7.24 (d, J = 10.4Hz, 1H), 3.56 (s, 2H), 1.27 (s, 12H).

[0342] Example 9: Preparation of 5-formyl-2-methyl-3-(2-trimethylsilylethoxymethyl)-imidazole-4-carboxylic acid (C1)

[0343]

[0344] Step 1. Dess-Martin reagent (2.97 g, 7.00 mmol, 2.17 mL, 1.5 eq) was added to a mixture of [5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)-imidazol-4-yl]methanol (1.50 g, 4.67 mmol, 1 eq) in DCM (15.0 mL) at 0°C. The mixture was stirred at 25°C for 2 hours, diluted with DCM (10.0 mL), and then filtered to remove insolubles. The filtrate was diluted with H2O (10.0 mL) and extracted with DCM (10.0 mL*3). The combined organic layers were washed with brine (10.0 mL*3), dried over Na2SO4, filtered, and then concentrated under reduced pressure. The residue was purified by flash silica gel chromatography ( 10g Sepa Silica gel flash column, elution with 0 to 10% ethyl acetate in petroleum ether gradient at 55 mL / min) to give 5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)-imidazole-4-carbaldehyde (710 mg, 2.22 mmol, 47.63% yield) as a colorless oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ = 9.60 (s, 1H), 5.75-5.68 (m, 2H), 3.62-3.53 (m, 2H), 2.55-2.46 (m, 3H), 0.94-0.84 (m, 2H), -0.02 (s, 9H).

[0345] Step 2. Pd(dppf)Cl (80.2 mg, 109 μmol, 0.05 eq) and TEA (665 mg, 6.58 mmol, 915 μL, 3 eq) were added to a solution of 5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazole-4-carbaldehyde (700 mg, 2.19 mmol, 1 eq) in DMF (10.0 mL) and MeOH (5.00 mL) under N. The mixture was degassed under vacuum and purged with CO several times. The mixture was stirred at 80° C. under CO (2.19 mmol, 1 eq) (50 psi) for 16 h. The mixture was concentrated in vacuo. The crude product was chromatographed on silica gel eluting with petroleum ether / ethyl acetate=5:1 to give methyl 5-formyl-2-methyl-3-(2-trimethylsilylethoxymethyl)imidazole-4-carboxylate (550 mg, 1.84 mmol, 84.06% yield) as a yellow solid.1 H NMR (400MHz, CDCl3) δ = 10.4 (s, 1H), 5.78 (s, 2H), 3.98 (s, 3H), 3.64-3.47 (m, 2H), 2.56 (s, 3H), 0.92-0.86 (m, 2H), -0.03 (s, 9H).

[0346] Step 3. LiOH.H2O (210 mg, 5.03 mmol, 5 eq) was added to a mixture of 5-formyl-2-methyl-3-(2-trimethylsilylethoxymethyl)-imidazole-4-carboxylic acid methyl ester (300 mg, 1.01 mmol, 1 eq) in MeOH (2.00 mL) and H2O (0.6 mL) under N2. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove MeOH. HCl (1 N) was added to the mixture until pH = 5 to 6. The residue was diluted with H2O (5.00 mL) and extracted with EtOAc (5.00 mL*3). The combined organic layers were washed with brine (5.00 mL*3), dried over Na2SO4, filtered and then concentrated under reduced pressure to give a residue to afford 5-formyl-2-methyl-3-(2-trimethylsilylethoxymethyl)imidazole-4-carboxylic acid (200 mg, 694 μmol, 69.12% yield, 98.8% purity) as a white solid. 1 HNMR (400MHz, DMSO-d6) δ = 10.31 (s, 1H), 5.70 (s, 2H), 3.53-3.49 (m, 2H), 2.45 (s, 3H), 0.89-0.78 (m, 3H), -0.05--0.07 (m, 9H).

[0347] General Method A

[0348] Example 9: Preparation of [3a(4)Z]-6,9,15,16-tetramethyl-9,10,11,12-tetrahydro-15H-1,17-(ethylenediyl)pyrazolo[4,3-n]dipyrrolo[3,2-g:3',4'-j][1,5]oxazacyclopentadecane-3,8(2H,5H)-dione (Compound 1)

[0349]

[0350] Step 1. Pd(dppf)Cl2 (100 mg, 138 μmol, 0.1 eq) was added to a solution of N-[3-(4-bromo-1,5-dimethyl-pyrazol-3-yl)oxypropyl]-N-methyl-carbamic acid tert-butyl ester (500 mg, 1.38 mmol, 1 eq), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one (643.73 mg, 2.48 mmol, 1.8 eq), Na2CO3 (438 mg, 4.14 mmol, 3 eq) in dioxane (20 mL) and H2O (4 mL). The reaction mixture was stirred at 100° C. for 2 h, cooled and concentrated in vacuo. The residue was purified by column chromatography on silica gel (DCM: MeOH = 25: 1 to 10: 1) to give tert-butyl N-[3-[1,5-dimethyl-4-(2-oxoindolin-5-yl)pyrazol-3-yl]oxypropyl]-N-methyl-carbamate (450 mg, 662 μmol, 47.9% yield, 61% purity) as a yellow oil. LCMS m / z 415.2 ((M+1).

[0351] Step 2. A solution of 5-[1,5-dimethyl-3-[3-(methylamino)propoxy]pyrazol-4-yl]indolin-2-one (160 mg, 508 μmol, 1 eq), 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (116.90 mg, 763.40 μmol, 1.5 eq), 1-methylimidazole (417 mg, 5.09 mmol, 0.040 mL, 10 eq) and [chloro(dimethylamino)methylene]-dimethylammonium hexafluorophosphate (185 mg, 662 μmol, 1.3 eq) in MeCN (30 mL) was stirred at 25° C. for 1 h. The reaction mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel (DCM: MeOH = 30: 1 to 10: 1) to give N-[3-[1,5-dimethyl-4-(2-oxoindolin-5-yl)pyrazol-3-yl]oxypropyl]-2-formyl-N,5-dimethyl-1H-pyrrole-3-carboxamide (50 mg, 0.0745 mmol, 14.6% yield, 67% purity) as a yellow solid. LCMS m / z 450.2 (M+1).

[0352] Step 3. At 25°C, piperidine (14.2 mg, 0.167 mmol, 1.5 eq) was added to a mixture of N-[3-[1,5-dimethyl-4-(2-oxoindoline-5-yl)pyrazol-3-yl]oxypropyl]-2-formyl-N,5-dimethyl-1H-pyrrole-3-carboxamide (50 mg, 0.111 mmol, 1 eq) in EtOH (10 mL). The mixture was stirred at 80°C for 1 hour and concentrated in vacuo. The residue was purified by column chromatography on silica gel (DCM:MeOH=30:1 to 10:1) to give Compound 1 (2.9 mg, 5.86% yield, 97% purity) as an orange solid.

[0353] Example 10: Compounds 2 to 8 were prepared using general method A using the corresponding bromopyrazole analogs A1, A2, A3, A4, A5 or A6, commercially available oxindole boronate ester 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one or 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one, and pyrrole or imidazole aldehyde 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid, 2-formyl-1H-pyrrole-3-carboxylic acid or 5-formyl-2-methyl-3-(2-trimethylsilylethoxymethyl)imidazole-4-carboxylic acid.

[0354] Compound 8 was obtained using an additional deprotection step: TFA (1.54 g, 13.5 mmol, 1 mL, 201 eq) was added to a mixture of SEM-protected compound 8 (40.0 mg, 0.067.0 mmol, 1 eq) based on the imidazole ring in DCM (3 mL). The mixture was stirred at 25 ° C for 1 hour and then concentrated under reduced pressure. The residue was purified by preparative-HPLC (column: Phenomenex C18 150*25mm*10μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 9% to 39%, 8min) to obtain compound 8 (5.48 mg, 0.012 mmol) as a yellow solid.

[0355]

[0356]

[0357]

[0358] Example 11: Preparation of [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,16-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecane-3,8(5H,9H)-dione (Compound 9)

[0359]

[0360]

[0361] Step 1. Under N2, K2CO3 (2.99 g, 21.6 mmol, 2 eq) was added to a mixture of 5-bromo-1-chloro-3-fluoro-2-nitrobenzene (2.75 g, 10.8 mmol, 1 eq) and dimethyl malonate (1.86 g, 14.0 mmol, 1.61 mL, 1.3 eq) in DMF (30 mL). The mixture was stirred at 80°C for 12 hours. The residue was diluted with H2O (15.0 mL) and then extracted with EtOAc (15.0 mL*3). The combined organic layers were washed with brine (15 mL*3), dried over Na2SO4, filtered and then concentrated under reduced pressure to obtain a residue. The residue was purified by flash silica gel chromatography ( 20g Sepa Silica gel flash column, 0 to 16% ethyl acetate / petroleum ether gradient eluent at 80 mL / min) to give dimethyl 2-(5-bromo-3-chloro-2-nitrophenyl)malonate (3.20 g, crude) as a yellow solid. LCMS: m / z 367.7 (M+1)

[0362] Step 2. Pd(dppf)Cl (619 mg, 845 μmol, 0.1 eq) and KOAc (2.49 g, 25.3 mmol, 3 eq) were added to a mixture of dimethyl 2-(5-bromo-3-chloro-2-nitrophenyl)malonate (3.1 g, 8.46 mmol, 1 eq) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (2.36 g, 9.30 mmol, 1.1 eq) in dioxane (35.0 mL) under N. The mixture was stirred at 80° C. for 5 h. The reaction mixture was concentrated under reduced pressure to remove dioxane. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate = 1 / 0 to 5 / 1) to give compound dimethyl 2-[3-chloro-2-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]malonate (2.00 g, 4.84 mmol, 57.17% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ = 7.90 (d, J = 0.8Hz, 1H), 7.81 (d, J = 0.8Hz, 1H), 5.10 (s, 1H), 3.71 (s, 6H), 1.32 (s, 12H).

[0363] Step 3. Under N2, di-tert-butyl(cyclopentyl)phosphine; dichloropalladium; iron (42.3 mg, 64.9 μmol, 0.1 eq) and Cs2CO3 (635 mg, 1.95 mmol, 3 eq) were added to a mixture of dimethyl 2-[3-chloro-2-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]malonate (295 mg, 0.714 mmol, 1.1 eq) and tert-butyl N-[(1R)-2-[[5-bromo-2-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methoxy]-1-methyl-ethyl]-N-methyl-carbamate (320 mg, 0.649 mmol, 1 eq) in dioxane (5.00 mL) and H2O (0.8 mL). The mixture was stirred at 70 ° C for 2 hours. The reaction mixture was concentrated under reduced pressure to remove dioxane. The residue was purified by preparative-TLC (SiO2, petroleum ether: ethyl acetate = 1: 1) to give dimethyl 2-[5-[5-[[(2R)-2-[tert-butoxycarbonyl (methyl) amino] propoxy] methyl]-2-methyl-3-(2-trimethylsilylethoxymethyl) imidazole-4-yl]-3-chloro-2-nitrophenyl] malonate (250 mg, 0.312 mmol, 48.09% yield) as a colorless oil. LCMS: m / z 699.3 (M+1).

[0364] Step 4. HCl / dioxane (4M, 2.50 mL, 69.9 eq) was added to a mixture of 2-[5-[5-[[(2R)-2-[tert-butoxycarbonyl(methyl)amino]propoxy]methyl]-2-methyl-3-(2-trimethylsilylethoxymethyl)imidazol-4-yl]-3-chloro-2-nitrophenyl]malonate (100 mg, 0.143 mmol, 1 eq) in DCM (2.00 mL). The mixture was stirred at 20 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove DCM to give 2-[3-chloro-5-[2-methyl-4-[[(2R)-2-(methylamino)propoxy]methyl]-1H-imidazole-5-yl]-2-nitrophenyl]malonate (80.0 mg) as a yellow solid. LCMS m / z 469.0 (M+1).

[0365] Step 5. [Chloro(dimethylamino)methylene]-dimethylammonium hexafluorophosphate (66.6 mg, 0.237 mmol, 1.5 eq) and 1-methylimidazole (38.9 mg, 0.475 mmol, 3 eq) were added to a mixture of dimethyl 2-[3-chloro-5-[2-methyl-4-[[(2R)-2-(methylamino)propoxy]methyl]-1H-imidazol-5-yl]-2-nitrophenyl]malonate (80.0 mg, 0.158 mmol, 1 eq, HCl) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (36.3 mg, 0.237 mmol, 1.5 eq) in MeCN (1.50 mL), and the mixture was stirred at 25° C. for 0.5 h. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was purified by preparative-TLC (SiO 2 , dichloromethane:methanol=10:1) to afford dimethyl 2-[3-chloro-5-[4-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-2-methyl-1H-imidazol-5-yl]-2-nitrophenyl]malonate (80.0 mg, 0.114 mmol, 72.45% yield) as a yellow oil. LCMS m / z 604.3 (M+1).

[0366] Step 6. LiCl (22.4 mg, 0.529 mmol, 4 eq) was added to a mixture of dimethyl 2-[3-chloro-5-[4-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-2-methyl-1H-imidazol-5-yl]-2-nitrophenyl]malonate (80.0 mg, 0.132 μmol, 1 eq) in DMSO (1.50 mL) and H2O (0.3 mL). The mixture was stirred at 100°C for 12 hours. The filtrate was diluted with H2O (5.00 mL) and extracted with EtOAc (5.00 mL*3). The combined organic layers were washed with brine (5.00 mL*3), dried over Na2SO4, filtered and then concentrated under reduced pressure to give a residue. The residue was purified by preparative-TLC (SiO 2 , dichloromethane:methanol=10:1) to give methyl 2-[3-chloro-5-[4-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-2-methyl-1H-imidazol-5-yl]-2-nitrophenyl]acetate (70.0 mg, crude) as a yellow oil. LCMS m / z 546.0 (M+1).

[0367] Step 7. Pt / V / C (1.91 mg, 7.33 μmol, 0.1 eq) was added to a solution of methyl 2-[3-chloro-5-[4-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-2-methyl-1H-imidazol-5-yl]-2-nitrophenyl]acetate (40.0 mg, 0.0732 mmol, 1 eq) in MeOH (6.00 mL) and AcOH (0.100 mL) under N. The suspension was degassed under vacuum and purged with H several times. The mixture was stirred at 25° C. under H (15 psi) for 2 h. The reaction mixture was filtered and the filtrate was concentrated to give methyl 2-[2-amino-3-chloro-5-[4-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-2-methyl-1H-imidazol-5-yl]phenyl]acetate (35.0 mg, crude) as a yellow oil. LCMS m / z 516.2 (M+1).

[0368] Step 8. AcOH (0.4 mg, 0.0068 mmol, 0.1 eq) was added to a mixture of methyl 2-[2-amino-3-chloro-5-[4-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-2-methyl-1H-imidazol-5-yl]phenyl]acetate (35.0 mg, 67.8 μmol, 1 eq) in MeOH (2.00 mL), and the mixture was stirred at 70° C. for 12 h. The reaction mixture was concentrated under reduced pressure to remove MeOH to give compound N-[(1R)-2-[[5-(7-chloro-2-oxoindolin-5-yl)-2-methyl-1H-imidazol-4-yl]methoxy]-1-methylethyl]-2-formyl-N,5-dimethyl-1H-pyrrole-3-carboxamide (25.0 mg, crude) as a yellow oil. LCMS m / z 484.2 (M+1).

[0369] Step 9. Piperidine (0.44 mg, 0.0052 mmol, 0.1 eq) was added to a mixture of N-[(1R)-2-[[5-(7-chloro-2-oxoindolin-5-yl)-2-methyl-1H-indazol-4-yl]methoxy]-1-methylethyl]-2-formyl-N,5-dimethyl-1H-pyrrole-3-carboxamide (25.0 mg, 0.052 mmol, 1 eq) in EtOH (2.00 mL). The mixture was stirred at 80° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove EtOH. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25mm*10μm; mobile phase: [water(FA)-ACN]; B%: 10% to 40%, 10 min) to give Compound 9 (2.99 mg, 0.0047 mmol, 9.13%) as an orange solid. 1 H NMR (400MHz, DMSO-d6) δ = 12.45-11.88 (m, 1H), 11.51-11.09 (m, 2H), 8.37 ( s,1H),8.14-7.98(m,1H),7.79-7.51(m,1H),7.49-7.23(m,2H),6.39-6.2 2(m,1H),4.83-4.70(m,1H),4.47-4.33(m,2H),3.76(d,J=1.2Hz,2H),2.8 4-2.78(m,3H),2.43-2.39(m,3H),2.29(d,5.2Hz,3H),1.29-1.16(m,3H). LCMS m / z 466.1(M+1).

[0370] Example 12: Preparation of [3a(4)Z,10R]-6,9,10,15-tetramethyl-3,8-dioxo-3,5,8,9,10,11,13,15-octahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecane-20-carbonitrile (Compound 10)

[0371]

[0372] Step 1. KNO3 (3.03 g, 30.0 mmol, 2.0 eq) was added to a solution of 3-bromo-5-fluoro-benzonitrile (3.00 g, 15.0 mmol, 1 eq) in H2SO4 (20 mL) at 0°C. The mixture was quenched with water (20 mL) at 0°C and extracted with ethyl acetate (25 mL x 3), the combined organic phases were dried over anhydrous sodium sulfate, filtered and then concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 2 / 1) to give 5-bromo-3-fluoro-2-nitrobenzonitrile (130 mg, 0.53 mmol, 3.54% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ = 8.44 (dd, J = 2.0, 10.4Hz, 1H), 8.39 (t, J = 1.8Hz, 1H).

[0373] Step 2. K2CO3 (1.47 g, 10.6 mmol, 2 eq) was added to a solution of 5-bromo-3-fluoro-2-nitrobenzonitrile (1.30 g, 5.31 mmol, 1.0 eq), dimethyl malonate (841 mg, 6.37 mmol, 1.2 eq) in DMF (15 mL). The mixture was stirred at 80 ° C for 17 hours. The mixture was quenched with water (20 mL) and extracted with ethyl acetate (25 mL×3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered and then concentrated to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=20 / 1 to 2 / 1) to obtain dimethyl 2-(5-bromo-3-cyano-2-nitrophenyl) malonate (1.05 g, 2.94 mmol, 55.4% yield) as a colorless oil. 1 H NMR (400MHz, DMSO-d6) δ = 8.57 (d, J = 2.0 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 5.53 (s, 1H), 3.69 (s, 6H).

[0374] Step 3. A mixture of dimethyl 2-(5-bromo-3-cyano-2-nitrophenyl)malonate (2.00 g, 5.60 mmol, 1.0 eq), [3-[[(2R)-2-[tert-butoxycarbonyl(methyl)amino]propoxy]methyl]-1-methylpyrazol-4-yl]boronic acid (9.16 g, 28.0 mmol, 5.0 eq), di-tert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (365 mg, 0.56 mmol, 0.1 eq), KCO (2.32 g, 16.8 mmol, 3.0 eq) in dioxane (40 mL) and H0 (10 mL) was degassed and purged with N3 for 3 times, and then the mixture was stirred at 70°C under N atmosphere for 3 hours. The mixture was dried over anhydrous sodium sulfate, filtered and then concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 5 / 1 to 0 / 1) to give dimethyl 2-[5-[3-[[(2R)-2-[tert-butoxycarbonyl(methyl)amino]propoxy]methyl]-1-methylpyrazol-4-yl]-3-cyano-2-nitrophenyl]malonate (1.72 g, 3.07 mmol, 54.9% yield) as an orange oil. 1 H NMR (400MHz, DMSO-d6) δ = 8.43 (d, J = 2.0Hz, 1H), 8.13 (s, 1H), 7.61 (d, J = 1.6Hz, 1H), 5.60 (s, 1H), 4.46-4. 41(m,2H),4.38-4.32(m,2H),3.92(s,3H),3.79(s,3H),3.72(s,6H),2.63(d,J=12.8Hz,3H),1.37(s,9H).

[0375] Step 4. HCl / dioxane (4M, 0.036 mL, 1.0 eq) was added to a solution of dimethyl 2-[5-[3-[[(2R)-2-[tert-butoxycarbonyl(methyl)amino]propoxy]methyl]-1-methyl-pyrazol-4-yl]-3-cyano-2-nitrophenyl]malonate (80.0 mg, 0.143 mmol, 1.0 eq) in DCM (4 mL). The mixture was stirred at 25 °C for 1 hour. The mixture was concentrated to give dimethyl 2-[3-cyano-5-[1-methyl-3-[[(2R)-2-(methylamino)propoxy]methyl]pyrazol-4-yl]-2-nitrophenyl]malonate (80 mg, crude) as a brown oil. LCMS m / z 460.3 (M+1).

[0376] Step 5. 1-Methylimidazole (179 mg, 2.18 mmol, 10.0 eq) and [chloro(dimethylamino)methylene]-dimethylammonium hexafluorophosphate (91.6 mg, 0.326 mmol, 1.5 eq) were added to a solution of dimethyl 2-[3-cyano-5-[1-methyl-3-[[(2R)-2-(methylamino)propoxy]methyl]pyrazol-4-yl]-2-nitrophenyl]malonate (100 mg, 0.217 mmol, 1.0 eq) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (40.0 mg, 0.261 mmol, 1.2 eq) in ACN (10 mL). The mixture was stirred at 20° C. for 1 hour. The mixture was concentrated to give a residue. The residue was purified by column chromatography (SiO2, DCM / MeOH=1 / 0 to 10 / 1) to give dimethyl 2-[3-cyano-5-[3-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-1-methylpyrazol-4-yl]-2-nitrophenyl]malonate (60.0 mg, 0.087 mmol, 40.0% yield) as a red solid. LCMS m / z 595.1 (M+1).

[0377] Step 6. LiCl (17.8 mg, 0.42 mmol, 5.0 eq) was added to a solution of dimethyl 2-[3-cyano-5-[3-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-1-methylpyrazol-4-yl]-2-nitrophenyl]malonate (50.0 mg, 0.084 mmol, 1.0 eq) in DMSO (2 mL) and H2O (0.4 mL). The mixture was stirred at 90°C for 20 hours. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (5 mL×3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered and then concentrated to give methyl 2-[3-cyano-5-[3-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-1-methyl-pyrazol-4-yl]-2-nitrophenyl]acetate (80 mg, crude) as a colorless oil. LCMS m / z 537.1 (M+1).

[0378] Step 7. Fe (41.6 mg, 0.746 mmol, 5.0 eq) was added to a solution of methyl 2-[3-cyano-5-[3-[[(2R)-2-[(2-formyl-5-methyl-1H-pyrrole-3-carbonyl)-methylamino]propoxy]methyl]-1-methylpyrazol-4-yl]-2-nitrophenyl]acetate (80.0 mg, 0.149 mmol, 1.0 eq) in AcOH (2 mL). The mixture was stirred at 90° C. for 1 hour. The mixture was filtered and concentrated to give a residue. The residue was purified by preparative-HPLC (TFA conditions; column: Welch Xtimate C18 150*25mm*5μm; mobile phase: [water (TFA)-ACN]; B%: 21% to 51%, 10 min) to give compound 10 (2.25 mg, 2.55% yield) as an orange solid. 1 H NMR (400MHz, CDCl3) δ = 11.28 (d, J = 4.0Hz, 1H), 8.49 (s, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.35 (d, J = 2.0Hz, 1H), 6.36 (d, J = 2.4Hz, 1H), 5.38-5. 33(m,1H),5.09-4.96(m,1H),4.55-4.51(m,2H),3.96(s,3H),3.95-3 .93(m,1H),3.84-3.77(m,1H),2.90(s,3H),2.46(s,3H),1.26(s,3H). LCMS m / z 457.2(M+1).

[0379] Example 13: Compounds 11 to 13 were prepared following general method A using the corresponding bromopyrazole analogs A2a or A4, boronate D1 or commercially available oxindole boronate ester 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid.

[0380]

[0381]

[0382] Biochemical analysis

[0383] Example 14: Kinase binding analysis was performed using the general KINOME scanning protocol (Fabian, MA et al., "A small molecule-kinase interaction map for clinical kinase inhibitors", Nat. Biotechnol. 2005, 23(3): 329-36) at Eurofins / DiscoveRx. For most analyses, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage and incubated at 32°C with shaking until lysed. The lysate was centrifuged and filtered to remove cell debris. The remaining kinase was produced in HEK-293 cells and then DNA labeled for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to produce affinity resins for kinase analysis. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and reduce nonspecific binding. Binding reactions were assembled by combining kinase, ligand affinity beads and test compounds in 1x binding buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM DTT). All reactions were performed in polystyrene 96-well plates in a final volume of 0.135 mL. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1x PBS, 0.05% Tween 20). The beads were then resuspended in elution buffer (1x PBS, 0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The kinase concentration in the eluate is determined by qPCR. In this analysis, the results for the compounds tested at a given concentration are reported as "% Control", where lower values ​​indicate stronger binding in the matrix. % Control is calculated as (test compound signal - positive control signal) / (negative control signal - positive control signal) x 100. The dissociation constant (Kd) of the test compound-kinase interaction is calculated by determining the amount of kinase captured on the solid support as a function of the test compound concentration.

[0384] Table 1. Tyrosine kinase selectivity properties of compounds 1 to 5 (% of control at 1 μM)

[0385]

[0386]

[0387]

[0388]

[0389]

[0390] Table 2. Dissociation constants (Kd) relative to the JAK family

[0391]

[0392]

[0393] Example 15: Phosphorylation of STAT5 in IFNa-stimulated CD3+ T cells

[0394] Inhibition of STAT5 phosphorylation in IFNa-stimulated CD3+ T cells was assessed at HD Bioscience, Inc. (6122 Nancy Ridge Drive, San Diego, CA 92121).

[0395] PBMC separation: Human whole blood was obtained from San Diego Blood Bank in a tube containing heparin. Peripheral blood mononuclear cells (PBMC) were separated by density gradient centrifugation using lymphoprep. Briefly, 15 mL of lymphoprep buffer was added to the bottom of the SepMate tube. Soon, the tube was inverted. 8 ml of blood was diluted using Robosep buffer. Blood / Robosep buffer mixture was added to the tube and centrifuged at room temperature for 10 minutes at 1200 x g. The Robosep buffer was used at room temperature to wash the precipitate by centrifuge 300 x g for 8 minutes. The precipitate was resuspended in 10 mL of 1 x RBC lysis buffer and cultivated at room temperature for 10 minutes. 20 mL of Robosep buffer was added to stop the reaction. The precipitate was inverted and resuspended in 2 mL of Robosep buffer.

[0396] PBMC inoculation and IFNa treatment: PBMC cells were resuspended at a concentration of 1.25e6 cells / mL. CD3 antibody was added at a ratio of 1uL antibody / 90μL cell suspension. 80μL / well (1e5 cells) were inoculated in a 96-well plate. The cells were treated with the specified compounds and incubated at 37°C for 30 minutes. 20μL IFNa (PBL, catalog number 11101) was added to the cells and incubated at 37°C for 30 minutes.

[0397] Fixation, permeabilization and intracellular staining: Immediately after stimulation, PBMC cells were fixed with 500 μL ( / well) of preheated 1X dissolution / fixation buffer for 10 minutes at 37°C. The cells were washed with 300 μL FACS staining buffer at 500 x g using a centrifuge for 5 minutes. The cells were thoroughly resuspended in 500 μL BD Phosflow Perm buffer III. The cells were allowed to permeabilize for 30 minutes in the dark at 4°C. The cells were further washed with 500 μL 1X permeabilization buffer at 500 x g using a centrifuge for 5 minutes and resuspended in 100 μL 1X permeabilization buffer (BD Biosciences, catalog number 562077) containing 2.5 μL pSTAT5 antibodies. The cells were stained at room temperature for 1 hour, then centrifuged at 500 x g for 5 minutes to remove the supernatant. The cells were washed with 300 μL FACS staining buffer using a centrifuge and resuspended in 300 μL FACS buffer. pSTAT5 expression was analyzed via flow cytometry. The results are shown in Table 3.

[0398] Table 3

[0399] Compound 2 Compound 5 Compound 7 <![CDATA[IC 50 (nM)]]> 146.8 15.7 48.9

Claims

1. A compound of formula I or a pharmaceutically acceptable salt thereof, in A is B is Each L is independently -C(R 3 )(R 4 )-、-C(O)-、-O-、-N(R 5 )-, -S-, -S(O)- or -S(O)2-, with the restriction (L) n Does not include –OO-, –OS-, -SS-, or –ON(R 5 )-key, and (L) n -N(R 9 )-Not included-ON(R 9 )-or–SN(R 9 )-key; Y and Y 1 Each independently is O or S; R 1 , R 1a and R 2 Each is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NRa R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NRe C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution; R 2a , R 5 , R 8 and R 9 Each is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 aryl or 5 to 10 membered heteroaryl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4 to 8 membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f, -SR e , -S(O)R e , -S(O)2R e , -S(O)NR e R f , -S(O)2NR e R f , -NR e R f , -NR e , -NR f , -NR e , -NR f , -NR e , -NR e R f , -NR e , -NR f , -NR e , -NR f , -NR e , -NR e R f , -NR e , -NR e R f , -C(O)R e , -C(O)OR e , -C(O)NR e R f , -PR e R f , -P(O)R e R f , -P(O)2R e R f , -P(O)NR e R f , -P(O)2NR e R f , -P(O)OR e , -P(O)2OR e , substituted by -CN or -NO2; R 2bis C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl or 3-4 membered heterocycloalkyl, wherein each hydrogen atom in C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C4 cycloalkyl and 3-4 membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, -O(H or C1-C2 alkyl), -OC(O)C1-C2 alkyl, -OC(O)N(H or C1-C2 alkyl)2, -OS(O)C1-C2 alkyl, -OS(O)2C1-C2 alkyl or -OS(O) C2 alkyl, -OS(O)N(H or C1-C2 alkyl)2, -OS(O)2N(H or C1-C2 alkyl)2, -S(H or C1-C2 alkyl), -S(O)C1-C2 alkyl, -S(O)2C1-C2 alkyl, -S(O)N(H or C1-C2 alkyl)2, -S(O)2N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)C(O)C1-C2 alkyl, -N(H or C1-C2 alkyl) C(O)O(H or C1-C2 alkyl), -N(H or C1-C2 alkyl)C(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)2C1-C2 alkyl, -N(H or C1-C2 alkyl)S(O)N(H or C1-C2 alkyl)2, -N(H or C1-C2 alkyl)S(O)2N(H or C1-C2 alkyl)2, -C(O)C1-C2 alkyl , -C(O)O(H or C1-C2 alkyl), -C(O)N(H or C1-C2 alkyl)2, -P(H or C1-C2 alkyl)2, -P(O)(H or C1-C2 alkyl)2, -P(O)2(H or C1-C2 alkyl)2, -P(O)N(H or C1-C2 alkyl)2, -P(O)2N(H or C1-C2 alkyl)2, -P(O)O(H or C1-C2 alkyl), -P(O)2O(H or C1-C2 alkyl), -CN or -NO2; Each R 3 and R 4 are independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR c 、-OC(O)R c 、-OC(O)NR c R d 、-OC(=N)NR c R d 、-OS(O)R c 、-OS(O)2R c 、-OS(O)NRc R d 、 -OS(O)2NR c R d 、 -SR c 、 -S(O)R c 、 -S(O)2R c 、 -S(O)NR c R d 、 -S(O)2NR c R d 、 -NR c R d 、 -NR c 、 -NR d 、 -N(C(O)R c )(C(O)R d 、 -NR c 、 -NR d 、 -NR c C(O)NR c R d 、 -NR c C(=N)NR c R d 、 -NR c 、 -NR d 、 -NR c S(O)2R d 、 -NR c S(O)NR c R d 、 -NR c S(O)2NR c R d 、 -C(O)R c 、 -C(O)OR c 、 -C(O)NR c R d 、 -C(=N)NR c R d 、 -PR c R d 、 -P(O)R c R d 、 -P(O)2R c R d 、 -P(O)NR c R d 、 -P(O)2NR c R d 、 -P(O)OR c 、 -P(O)2OR c 、 -CN, -NO2, or R 3 、 R 4 及R 5The two of them together with the atoms to which they are attached form a C3-C6 cycloalkyl or a 4- to 8-membered heterocycloalkyl, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution; R 6 and R 7 Each is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OR a 、-OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a 、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2; or R 6 and R 7 Together with the carbon to which it is attached, it forms a C4-C6 cycloalkyl, a 4- to 7-membered heterocycloalkyl, or a C6-C 10 Aryl, among which C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl, 5- to 10-membered heteroaryl, or 4- to 7-membered heterocycloalkyl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e Rf 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2 substitution; Each R a , R b , R c , R d , R e and R f are independently selected from H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, C1-C6 alkyl-C6-C 10 The group consisting of aryl and 5- to 10-membered heteroaryl; and n is 2, 3, 4, 5, 6, 7 or 8.

2. The compound according to claim 1, which has formula II or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1, which has formula III or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 or 2, which has formula IV or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 or 2, which has formula V or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 or 2, which has formula VI or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1 to 3, which has the formula VII or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 or 2, which has the formula VIII or a pharmaceutically acceptable salt thereof.

9. The compound according to any one of claims 1 to 3, which has the formula IX or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1 or 2, which has the formula X or a pharmaceutically acceptable salt thereof.

11. The compound according to any one of claims 1 to 3, which has the formula XI or a pharmaceutically acceptable salt thereof.

12. The compound according to any one of claims 1 to 3, which has the formula XII or a pharmaceutically acceptable salt thereof.

13. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 1 When present, it is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 1 It is H, -CN or methyl.

14. The compound according to any one of claims 1 to 3, 5 to 7, 9, 11, 12 or 13, or a pharmaceutically acceptable salt thereof, wherein R 1a When present, it is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2, or R 1a It is H, -CN or methyl.

15. The compound according to any one of claims 1 to 5, 7, 8, 11, 13 or 14, or a pharmaceutically acceptable salt thereof, wherein R 2 When present, it is H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloamino, 4- to 8-membered heterocycloalkyl, C6-C 10 Aryl, 5- to 10-membered heteroaryl, -OC(O)R a 、-OC(O)NR a R b 、-OS(O)R a、-OS(O)2R a 、-SR a 、-S(O)R a 、-S(O)2R a 、-S(O)NR a R b 、-S(O)2NR a R b 、-OS(O)NR a R b 、-OS(O)2NR a R b 、-NR a R b 、-NR a C(O)R b 、-NR a C(O)OR b 、-NR a C(O)NR a R b 、-NR a S(O)R b 、-NR a S(O)2R b 、-NR a S(O)NR a R b 、-NR a S(O)2NR a R b 、-C(O)R a 、-C(O)OR a 、-C(O)NR a R b , -PR a R b 、-P(O)R a R b 、-P(O)2R a R b 、-P(O)NR a R b 、-P(O)2NR a R b 、-P(O)OR a 、-P(O)2OR a , -CN or -NO2, wherein C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 4- to 8-membered heterocycloalkyl, C6-C 10 Each hydrogen atom in the aryl or 5- to 10-membered heteroaryl group is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NRe R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 2 When present, it is H, -CN or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)Re 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e R f 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 2 When present, it is H, -CN or methyl.

16. A compound according to any one of claims 1 to 4, 6, 9, 10 or 12 to 15, or a pharmaceutically acceptable salt thereof, wherein R 2a When present, it is H or C1-C6 alkyl, wherein each hydrogen atom in the C1-C6 alkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, -OR e 、-OC(O)R e 、-OC(O)NR e R f 、-OS(O)R e 、-OS(O)2R e 、-OS(O)NR e R f 、-OS(O)2NR e R f 、-SR e 、-S(O)R e 、-S(O)2R e 、-S(O)NR e R f 、-S(O)2NR e R f 、-NR e R f 、-NR e C(O)R f 、-NR e C(O)OR f 、-NR e C(O)NR e R f 、-NR e S(O)R f 、-NR e S(O)2R f 、-NR e S(O)NR e R f 、-NR e S(O)2NR e R f 、-C(O)R e 、-C(O)OR e 、-C(O)NR e R f , -PR e R f 、-P(O)R e R f 、-P(O)2R e R f 、-P(O)NR e R f 、-P(O)2NR e Rf 、-P(O)OR e 、-P(O)2OR e , -CN or -NO2; or R 2a When present, it is H or methyl.

17. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 2b When present, it is C1-C4 alkyl or C3-C4 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl and C3-C4 cycloalkyl is independently optionally substituted with deuterium or halogen; or R 2b It is methyl, ethyl, isopropyl or cyclopropyl.

18. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein n is 3.

19. The compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein n is 4.

20. The compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein n is 5.

21. The compound according to any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein n is 6.

22. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein each L is independently selected from -C(O)-, -O-, -CH2-, -C(H)(CH3)-, -C(H)(OH)-, -C(H)(C(O)OR c )-、-C(H)(C(O)NR c R d )-, -NH- and -NCH3-; or each L is independently selected from the group consisting of -C(O)-, -O-, -CH2-, -C(H)(CH3)-, -C(H)(OH)-, -C(H)(C(O)OR c )- and -C(H)(C(O)NR c R d )-composed of groups.

23. The compound according to any one of claims 1 or 13 to 22, or a pharmaceutically acceptable salt thereof, wherein Y is O.

24. The compound according to any one of claims 1 or 13 to 23, or a pharmaceutically acceptable salt thereof, wherein Y 1 It's O.

25. The compound according to any one of claims 1 or 13 to 25, or a pharmaceutically acceptable salt thereof, wherein R 6 When present, it is independently H, deuterium, fluorine, chlorine, -CN or methyl.

26. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R 7 are independently H, deuterium, fluorine, chlorine, -CN or methyl.

27. A compound according to any one of claims 1 to 10 or 13 to 26, or a pharmaceutically acceptable salt thereof, wherein R 8 It is H or methyl.

28. A compound according to any one of claims 1 to 10 or 13 to 27, or a pharmaceutically acceptable salt thereof, wherein R 9 It is H or methyl.

29. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein - (L) n-is-(CH2)2-,-(CH2)3-,-(CH2)4-,-(CH2)5-,-(CH2)6-,-C(O)NH-(CH2)2O(CH2)2-,-C(O)N(CH3)-(CH2)2O(CH2)2-,-NHC(O)CH2O(CH2)2-,-N(CH3)-C(O)CH2O(CH2)2-,-CH2O(CH2)2-,-CH2O(CH2)3-,-CH2O(C(CH3)H)2-,-(CH2)2O(CH2)2-,-CH2OCH2(C(CH3)H)-,-(CH2)2O(CH2)2-,-CH2OCH2(C(CH3)H)-,-(CH2)2OCH2(C(CH3)H)-,-(CH2)2OCH2(C(CH3)H)-,-(CH2 )2S(CH2)2-、-O(CH2)2S(CH2)2-、-(CH2)2SO2(CH2)2-、-O(CH2)2SO2(CH2)2-、-(CH2)2SO(CH2)2-、-O(CH2)2SO(CH2)2-、-(CH2)2O(C(H)(C(O)N(H) (CH3))-CH2-、-(CH2)2O(C(H)(C(O)N(CH3)2)-CH2-、-(CH2)2O(C(H)(C(O)OCH3)-CH2-、-(CH2)3O(CH2)2-、-(CH2)2O(CH2)3-、-CH2CH(CH3)-O(CH2) 2-、-CH(CH3)-CH2O(CH2)2-、-O(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)2CH(CH3)-、-OCH2O(CH2)2-、-O-CH2CH(OH)CH2-、-O-(CH2)2O(CH2)2-、-O-CH2CH(CH3)-O(CH2)2-、-O-CH(CH3)-CH2O(CH2)2-、-O-(CH2)2NH-(CH2)2-、-O-CH2CH(CH3)-NH-(CH2)2-、-O-CH(CH3)-CH2NH-(CH2)2-、-O-CH(CH3)-CH2NH-(CH2)2-、-CH2NH -(CH2)2-、-(CH2)2NH-(CH2)2-、-CH2CH(CH3)-NH-(CH2)2-、-CH(CH3)-CH2NH-(CH2)2-、-O-(CH2)2N(CH3)-(CH2)2-、-O-CH2CH(CH3)-N(CH3)-(CH2) )2-、-O-CH(CH3)-CH2N(CH3)-(CH2)2-、-CH2N(CH3)-(CH2)2-、-CH2N(CH2CH3)-(CH2)2-、-CH2N((CH2)2CH3)-(CH2)2-、-CH2N(CH(CH3)2)-(CH2)2-、-(CH2)2N(CH3)-(CH2)2-, -CH2CH(CH3)-N(CH3)-(CH2)2- or -O-CH(CH3)-CH2N(CH3)-(CH2)2-; or -O(CH2)2-, -O(CH2)3-, -O(CH2)4-, -CH2OCH2(C(CH3)H)-, -CH2O(CH2)2- or -CH2O(CH2)3-; or -O(CH2)3-, -CH2OCH2(C(CH3)H)- or -CH2O(CH2)2-. 、 30. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of: [3a(4)Z]-6,9,15,16-tetramethyl-9,10,11,12-tetrahydro-15H-1,17-(ethylenediyl)pyrazolo[4,3-n]dipyrrolo[3,2-g:3',4'-j][1,5]oxazacyclopentadecen-3,8(2H,5H)-dione; [3a(4)Z]-6,9,15,16-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-20-chloro-6,10,15-trimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-20-chloro-10,15-dimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10S]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z]-20-chloro-6,9,15-trimethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-f]pyrazolo[4,3-m]pyrrolo[3,4-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-20-chloro-6,9,10,15-tetramethyl-10,11,13,16-tetrahydro-2H-1,17-(ethylenediyl)imidazo[4,5-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-6,9,10,15-tetramethyl-3,8-dioxo-3,5,8,9,10,11,13,15-octahydro-2H-1,17-(ethylenediyl)pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-20-carbonitrile; [3a(4)Z,10R]-20-fluoro-6,9,10,15,16-pentamethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; [3a(4)Z,10R]-20-chloro-6,9,10,15,16-pentamethyl-10,11,13,15-tetrahydro-2H-1,17-vinylpyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione; and [3a(4)Z,10R]-20-Fluoro-6,9,10,15-tetramethyl-10,11,13,15-tetrahydro-2H-1,17-vinyl-bridged pyrazolo[4,3-m]dipyrrolo[3,2-f:3',4'-i][1,4]oxazacyclopentadecen-3,8(5H,9H)-dione.

31. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 30 or a pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipients.

32. A method of treating a disease (such as an autoimmune disease) comprising administering to a subject in need of such treatment an effective amount of a compound according to any one of claims 1 to 30 or a pharmaceutically acceptable salt thereof.

33. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for use in a method of treating an autoimmune disease in a subject.

34. A compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease in a subject.

35. Use of a compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating an autoimmune disease in a subject.